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II 
 
 
Summary 
 
Neuropathic pain is a debilitating, chronic pain condition associated with inflammation or 
injury of peripheral and central nerves (Milligan and Watkins, 2009). The existing 
pharmacotherapies either lead to an inadequate pain relief or have psychomimetic side 
effects. Therefore, selective agonists targeting the peripherally expressed cannabinoid 
receptor 2 (CB2) came into the focus for the treatment of neuropathic pain and a number of 
studies have shown that CB2 is critically involved in the modulation of neuropathic pain 
responses. Recently, the widespread plant volatile ß-caryophyllene (BCP) was identified as a 
natural, selective CB2 receptors agonist, which is found in relatively high concentrations in 
many spice and food plants.  
The present study demonstrates that orally administered BCP ameliorated thermal 
hyperalgesia and mechanical allodynia in mice suffering from neuropathic pain with no 
cannabinoid-induced psychomimetic side effects. The pharmacological effects of BCP were 
mediated by CB2 receptors. Similarly, histological analyses revealed that BCP reduced the 
inflammatory response (glia activation) in the dorsal horns of lumbar spinal cord. Thus, the 
natural plant product BCP may be highly effective in the treatment of long lasting, debilitating 
pain states and highlights the role of dietary factors in the development and modulation of 
chronic pain conditions. 
Further, a second model for peripheral nerve injury was established. Repeated treatment 
with the chemotherapeutic agent paclitaxel induced a robust decrease of mechanical 
withdrawal latencies in CB2 receptor knockout mice. Wild type littermates in contrast showed 
less signs of neuropathic pain. These results suggest that CB2 receptor activation might 
protect against chemotherapeutic agent-induced neuropathic pain. 
Taken together, both experimental approaches emphasize the important role of CB2 
receptors in the control of neuropathic pain and their relevance as a possible therapeutic 
target to improve current neuropathic pain therapies. 
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1 INTRODUCTION 
Under normal conditions, the sensation of pain serves as a warning signal for the body to 
alert us to real or potential tissue damage. It triggers withdrawal responses and helps to 
protect the injured body part, which prevents from further tissue damage and facilitates 
healing. Under certain conditions pain can become a chronic state. Along with this, its 
warning function is lost and pain becomes a disease itself. If chronic pain is “caused by a 
lesion or disease of the somatosensory nervous system” (definition of the International 
Association for the Study of Pain; http://www.iasp-pain.org/AM/Template.cfm?Sectio 
n=Pain_Definitions#Nociceptive neuron) either in the periphery or at central sides it is 
referred to as neuropathic pain. As neuropathic pain can arise after any condition, which is 
associated with nerve injury, the causes are wide spread and include mechanical injury or 
surgery, diabetes, infection (Herpes zoster, HIV) and cancer; or pain can occur as a side 
effect of chemotherapeutic treatment (Costigan et al., 2009). According to the German 
Research Network on Neuropathic pain (http://www.neuro.med.tu-muenchen.de/dfns 
/uns/e_portrait.html) about 5  million people in Germany are suffering from neuropathic pain. 
These patients often describe the quality of their pain as burning, needle prick or electric 
shock-like or like walking on glass (American chronic pain association; 
http://www.theacpa.org/conditionDetail.aspx?id=29). Furthermore, this pain can occur 
spontaneous without obvious external reason, as the nerve injury leads to a pain facilitating 
state at peripheral, spinal and supraspinal sites. Due to a modified skin sensitivity normally 
innocuous stimuli like pressure and cold can lead to a pain sensation (mechanical or cold 
allodynia). Noxious stimuli (e.g. heat) in turn lead to an exaggerated pain response 
(hypersensitivity) (Costigan et al., 2009).  
The treatment of neuropathic pain is still a challenging issue as the common painkillers 
(ibuprofen, diclofenac, or paracetamol) are ineffective. Pharmacological treatments 
commonly comprise tricyclic antidepressants, anticonvulsants, opioids and N-methyl-D-
aspartate (NMDA) receptor antagonists. Often combination therapies are used to target 
different receptors and thereby increase the analgesic effects (Gilron et al., 2006). But still, a 
realistic goal for the treatment of neuropathic pain is to archive a pain relieve of about 30-
50 % (German Research Network on Neuropathic pain; http://www.neuro.med.tu-
muenchen.de/  dfns/patienten /Def_NeP.html#the). Thus, the need for the development of 
new, effective drugs is immense. 
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1.1 Pain processing  
Acute pain transmission is initiated by the activation of specialized receptors at the 
peripheral nerve terminal of primary nociceptive neurons (nociceptors) by specific stimuli like 
heat, pressure or chemicals. Nociceptors convert the stimulus into an electrical potential, 
which is transmitted through the axon from the periphery to the dorsal horn of the spinal cord 
(see Figure 1a; Milligan and Watkins, 2009). 
There are three major groups of primary sensory neurons: large, myelinated Aα and Aβ 
fibers, lightly myelinated Aδ fibers and unmyelinated C fibers. Large diameter Aα and Aβ 
fibers are fast-conducting and mainly respond to innocuous stimuli like vibration and light 
touch, but during disease condition they can also transmit pain signals (Julius and Basbaum, 
2001). Medium diameter Aδ and small diameter C fibers respond to noxious mechanical, 
thermal and chemical stimuli and project to second-order pain-projection neurons and 
nociceptive interneurons in lamina I, IV and V in the dorsal horn. Second-order pain-
projection neurons either ascend on the ipsilateral side or decussate to the contralateral side 
at the spinal cord level and join the ascending anterolateral system to the brain stem and 
brain, e.g. thalamic nuclei, primary and secondary somatosensory cortex and association 
cortex (Milligan and Watkins, 2009). 
1.2 Pathological pain processing: neuropathic pain  
After lesion or disease of the somatosensory system, a sustained nociceptive input can 
trigger a maladaptive plasticity in the nervous system that leads to the development of 
chronic neuropathic pain (Costigan et al., 2009). Peripheral nerve injury induces several 
pathological changes in the injured and neighboring neurons at peripheral and central sides.  
In the periphery, the injured tissue releases several inflammatory mediators. This 
“inflammatory soup” includes bradykinin, serotonin, prostaglandins, adenosine triphosphate 
(ATP) and protons, which increase the sensitivity and excitability of the nociceptive neurons 
either directly or by activation of intracellular signaling pathways (Julius and Basbaum, 2001; 
Ji et al., 2003). Calcitonin gene-related peptide (CGRP) and substance P induce hyperaemia 
and swelling. This facilitates the invasion of immune cells guided by chemokines to the side 
of injury. Immune cells in turn release pro-inflammatory mediators like prostaglandins and 
cytokines, e.g. interleukin (IL)-1β, IL-6, interferon-γ (INF-γ) and tumor necrosis factor α 
(TNFα) (Scholz and Woolf, 2007). The pro-inflammatory mediators account for 
hypernociception by either neurotoxic effects (Keswani et al., 2003) or by increasing 
spontaneous fiber activity and lowering activation thresholds (Schäfers et al., 2003; Cunha et 
al., 2005).  
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Figure 1 Normal and pathological pain processing. (a) Under normal conditions an acute 
pain stimulus, e.g. a pin prick, evokes an electrical signal that is transmitted by A-δ and C fibers to 
pain transmission neurons (PTNs) in the dorsal horn of the spinal cord, which then project to their 
supraspinal targets. (b) At spinal cord level, incoming signals from the periphery lead to a moderate 
release of excitatory amino acids (EAAs) and substance P from the presynaptic neuron. EAAs and 
substance P open α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA) and 
neurokinin receptor 1 (NK-1) receptor ion channels leading to a depolarization of the postsynaptic 
neuron. (c) Under pathological conditions a sustained input from the periphery leads to an enhanced 
excitatory amino acid (EAAs) and substance P release and the pain transmission neuron (PTN) is 
strongly depolarized. This unplugs magnesium (Mg
2+
) from NMDA receptors and allows calcium (Ca
2+
) 
to enter the neuron. An increase in intracellular calcium activates the production of nitric oxide (NO) by 
nitric oxide synthase. NO acts as a retrograde messenger and leads to a further release of EAAs from 
the presynaptic neuron. (d) Glia cells are activated by ATP, prostaglandins (PGs), NO, substance P 
and EAAs. They contribute to the development of neuropathic pain by the release of pro-inflammatory 
cytokines and further NO, prostaglandins, EAAs and ATP, which enhance the PTN excitability and the 
presynaptic release of EAAs. - Reprinted from Trends in Neurosciences, Volume 24, Linda R. 
Watkins, Erin D. Milligan, Steven F. Maier, Glial activation: a driving force for pathological pain, 450-
455, Copyright (2001), with permission from Elsevier. 
 
In the spinal cord, repetitive synaptic input from the periphery leads to alterations in the 
neuronal and biochemical processing, which leads to a pain-facilitating state in the dorsal 
horn referred to as central sensitization (Woolf, 1983). Central sensitization shares striking 
similarities with the long-term potentiation (LTP) in the hippocampus during learning and 
memory formation (Ji et al., 2003). Therefore, it is colloquially also named as the “pain 
memory”. 
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The early phase of central sensitization is characterized by activity-dependent plasticity. A 
co release of glutamate, substance P and CGRP leads to a strong and sustaining 
depolarization of the postsynaptic terminal, magnesium is removed from voltage-dependent 
NMDA receptors and allows a calcium influx into the neuron (see Figure 1c; Milligan and 
Watkins, 2009). Activation of NMDA receptors plays a key role in central sensitization, e.g. 
shown by a reduction of injury-induced pain in mice with a deletion of the NMDAR NR1 
subunit (South et al., 2003). The increase in intracellular calcium activates e.g. the 
production of NO by nitric oxide synthase. NO acts as a retrograde messenger and leads to 
a further release of transmitter from the presynaptic neuron (Watkins et al., 2001). High 
nociceptive input through the multiple receptors expressed on dorsal horn neurons (AMPA, 
NK1, tyrosinkinase receptor B (TrkB), metabotropic glutamate receptors (mGluR)) results in 
the activation of intracellular kinases, like protein kinase C (PKC), extracellular signal-related 
kinase (ERK) and p38 that alter ion channel kinetics and properties (Ji and Woolf, 2001; Ji et 
al., 2003).  
Secondary, a loss of inhibitory transmission is also contributing to the development of 
chronic pain. Brain-derived neurotrophic factor (BDNF), binding to TrkB receptors, acts on 
dorsal horn lamina I neurons causing a shift of the anion reversal potential. After this, γ-
amino butyric acid (GABA), released by inhibitory interneurons, leads to a paradoxical 
excitation and spontaneous activity of lamina I neurons (Coull et al., 2005, Keller et al., 
2007). Similarly, a degeneration of inhibitory GABAergic interneurons contributes to the 
development of pain (Scholz et al., 2005). 
Late-onset changes involve the activation of transcription factors and transcription of 
several genes, leading to structural changes. The receptor density, synthesis of ion channels 
and the production of prostaglandin E2 (PGE2) through cyclooxygenase 2 (COX2) is 
increased (Woolf and Salter, 2000; Ji and Woolf, 2001; Ji et al., 2003). PGE2 enhances the 
excitability of neurons to incoming stimuli and stimulate a further release of neurotransmitter 
(Ji et al., 2003). At this stage originally non-nociceptive Aβ fibers can also signal pain after 
mechanical stimulation, possibly also due to sprouting of these fibers to lamina II (Costigan 
et al., 2009). 
Taken together, these events manifest in symptoms like spontaneous pain, 
hypersensitivity and mechanical and cold allodynia (Costigan et al., 2009).  
 
 
 
 
 
 
INTRODUCTION 5 
 
 
 
Box 1 Animal models of neuropathic pain 
 
 
A Traumatic nerve injury models: SNL (spinal nerve ligation), where the L5 and L6 nerves are ligated; 
CCI (chronic constriction injury), where several loose ligations of the sciatic nerve are made; PSNL or 
PNL (partial sciatic nerve ligation), where 1/3 to 1/2 of the sciatic nerve is lightly ligated; SNI (spared 
nerve injury), where the common peroneal and tibial branches of the sciatic nerve are tightly ligated. B 
Disease or treatment-induced neuropathic pain models: Experimental autoimmune neuritis, where 
nerves are sensitized after immunisation with myelin or myelin proteins; Chemotherapeutic or 
antiretroviral drug treatment, which is neurotoxic for sensory nerves; diabetes-associated neuropathic 
pain, where diabetes is induced by streptozocin administration. - Reprinted from The Lancet, 
Volume 11, Margarita Calvo, John M Dawes, David LH Bennett, The role of the immune system in the 
generation of neuropathic pain, 629-642, Copyright (2012), with permission from Elsevier. 
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1.3 The dual role of glia cells in neuropathic pain  
More evidence is arising that glia cells contribute to the development of neuropathic pain, 
as activation and proliferation of glia cells in the dorsal horn of the spinal cord parallels the 
symptoms of neuropathic pain (Coyle, 1998).  
Glia cells are non-conducting, supporting cells and constitute 70 % of total cell population 
in the central nervous system (CNS) (Vallejo et al., 2010). They are divided into three 
subtypes: oligodendrocytes, astrocytes and microglia (Vallejo et al., 2010). Oligodendrocytes 
are responsible for the myelination of neuronal axons, while astrocytes encapsulate the 
synapses and stay in close contact with several neurons (Milligan and Watkins, 2009). 
Similar to neurons, astrocytes express several neurotransmitter receptors and voltage-gated 
ion channels and modulate synaptic neurotransmission by the release of neurotransmitters 
(e.g. glutamate and ATP) (Hald, 2009). Additionally, they maintain glutamate homeostasis by 
clearing glutamate from the synaptic cleft through glutamate transporter 1 and glutamate-
aspartate transporter (De Leo et al., 2006). Resident microglia, which are bone marrow-
derived haematopoietic cells, are the primary immune cells of the CNS and ubiquitously 
distributed throughout the brain and spinal cord (Inoue and Tsuda, 2009). While the cell 
bodies of microglia remain quiescent, the cell processes are highly motile while surveying the 
CNS for pathogens, damage or injury (Nimmerjahn et al., 2005). Microglia also express 
several neurotransmitter receptors and can be activated by ATP, NO, substance P and pro-
inflammatory cytokines (Milligan and Watkins, 2009). Due to their immune cell function 
microglia are also activated by the chemokine fractalkine (CX3CL1) through chemokine 
receptor CX3CR1 and Toll-like receptors (TLR) that are fundamental in recognizing lipids, 
carbohydrates, peptides and nucleic acids of pathogens (Scholz and Woolf, 2007; Nicotra et 
al., 2012). Especially TLR 4 and TLR 2 are key mediators of glia activation in the CNS after 
nerve injury (Tanga et al., 2005). Thus, it is not astonishing that activated microglia are early 
hallmarks of any disease in the CNS (Kreutzberg, 1996). 
Activated glia cells contribute to the development of neuropathic pain by the release of 
pro-inflammatory cytokines like TNFα, IL-1β, IL-6 as well as BDNF and nuclear factor-κB 
(NF-κB), which are released after intracellular p38 and ERK MAPK activation (Cao and 
Zhang, 2008; Ji et al., 2009). Pro-inflammatory cytokines like TNFα, IL-1β and IL-6 either 
mediate their action through direct modulation of neurons or indirect through activation of 
immune cell signaling pathways (Thacker et al., 2007). BDNF acts on dorsal horn lamina I 
neurons leading to an inversion of inhibitory GABA currents (Coull et al., 2005), while NFκB 
activation induces the synthesis of NO and PGE2, which further sensitize the dorsal horn 
neurons (Cao and Zhang, 2008). In astrocytes, the glutamate transporters become 
dysregulated and a decrease in glutamate reuptake could contribute to an increased synaptic 
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input (Ji et al., 2006). Consequently, inhibition of glia metabolism was shown to attenuate 
pain-related behavior in mouse models of neuropathic pain (Scholz and Woolf, 2007).  
Analysis of the time course of glia activation revealed that the activation of microglia 
precedes and most likely initiates astrogliosis. Thus, it was suggested that microglia are 
crucial for the development of neuropathic pain, while astrocytes maintain the prolonged pain 
state (Hald et al., 2009).  
However, the contribution of glia cells is more complex than being just the “bad guys”. It 
was also shown that glia cells have protective roles in neurodegenerative diseases, although 
their function here is still not fully understood. As immunocompetent cells they are 
responsible for clearing debris, for fighting infections by phagocytosis as well as for repairing 
processes (Streit, 2009). Weather glia activation becomes dysfunctional or beneficial, seems 
to depend on the context of activation. Studies with TNFα knockout mice showed that a lack 
of TNFα produces a late, exaggerated microglia response in mice exposed to acute nitric 
oxide excitotoxicity (Turrin, 2006). Thus, depending on the timing and context of TNFα action 
it may also be crucial for neuroprotection. Next, appropriate phagocytosis of apoptotic cells 
by glia was shown to suppress lipopolysaccharide (LPS)-induced production of pro-
inflammatory cytokines, suggesting that phagocytosis and clearance are beneficial 
(Tassiulas, 2009). Finally, glia cells also release some cytokines, which are associated with 
beneficial actions during pathological pain conditions. IL-4 and IL-10 are known to reverse 
pathological pain and promote neuronal survival (Milligan and Watkins, 2009).  
Due to their critical role in the development and maintenance, but also clearance of 
chronic pain states, glia cells display an interesting target for the treatment of pain. Recent 
evidences verified that ligands of the endocannabinoid system can modulate glia activation 
and in parallel decrease pain (see next chapters 1.4 and 1.5; Cabral and Marciano-Cabral, 
2005; Cabral and Griffin-Thomas, 2009). 
1.4 The endocannabinoid system 
The discovery of Δ9-tetrahydrocannabinol (Δ9-THC) as the major psychoactive compound 
in the essential oils of Cannabis Sativa L. in 1964 by Raphael Mechoulam and colleagues 
(Gaoni and Mechoulam, 1964) and finally the discovery and cloning of the cannabinoid 
receptor 1 (CB1) in 1990 (Matsuda et al., 1990) followed by the cannabinoid receptor 2 
(CB2) in 1993 (Munro et al., 1993) triggered important advances in endocannabinoid 
research.  
The endocannabinoid system comprises a signaling system including receptors, 
endogenous ligands and enzymes for synthesis and degradation of the endogenous ligands 
(see Figure 2). It is involved in the “fine tuning” of several processes in the body including 
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memory, movement, food intake, nociception and inflammation (Di Marzo and Matias, 2005; 
Hohmann and Suplita, 2006; Burstein and Zurier, 2009; Marsicano and Lafenêtre, 2009; El 
Manira and Kyriakatos, 2010). 
The two cannabinoid receptors are Gi/o-protein coupled receptors with seven 
transmembrane-domains. The CB1 receptor is one of the most abundant neuromodulatory 
receptors in the brain. It is expressed presynaptically on peripheral and central nerve 
terminals, especially in hippocampus, cortex, cerebellum, basal ganglia and brainstem 
(Wilson and Nicoll, 2002). The CB2 receptor is mainly expressed on peripheral immune cells, 
but was also identified on microglia in the CNS (Facci et al., 1995; Howlett et al., 2004; 
Maresz et al., 2005; Kleyer et al., 2012). CB2 receptor expression was also reported to be up 
regulated in astrocytes under pathological conditions (Benito et al., 2007; Garcia-Ovejero et 
al., 2009).  
In 1992 the arachidonic acid-derived lipid N-arachidonoylethanolamide (AEA; anandamide) 
was identified as the first endogenous ligand (endocannabinoid) for cannabinoid receptors 
(Devane, 1992). AEA is found in low amounts in the brain and is only a partial agonist for 
both receptors (Katona and Freund, 2012). Thus, it was likely that there should be another 
endogenous ligand with full agonist activity. Indeed, in 1995 2-arachidonoylglycerol (2-AG) 
was identified as the second endogenous ligand, which is a full agonist for CB1 and CB2 
receptors (Mechoulam et al., 1995). Moreover, 2-AG occurs in larger amounts in the brain 
and is now postulated to be the key endocannabinoid at central synapses (Katona and 
Freund, 2012). Both endocannabinoids are produced on demand, triggered by an increase in 
intracellular Ca2+ and activation of mGluRs in postsynaptic neurons (Straiker and Mackie, 
2006;  Katona  and  Freund, 2008). AEA  is synthesized  by a Ca2+  sensitive N-acyl 
phosphatidylethanolamine phospholipase D (NAPE-PLD), while 2-AG is synthesized by the 
the diacylglycerol lipases (DAGL) α and β (Piomelli, 2003). Endocannabinoids then travel 
retrogradely to activate presynaptically located CB1 receptors. As retrograde messengers 
they act as synaptic circuit breaker by closing calcium channels and opening potassium 
channels and thereby decreasing the presynaptic neurotransmitter release (Katona and 
Freund, 2008). For CB2 receptors the picture is yet not that clear if they modulate calcium 
transients (Beltramo, 2009), but recent reports suggest that CB2 receptor activation 
increases intracellular calcium (Shoemker et al., 2005; Gertsch et al., 2008). 
Typical for Gi/o-protein coupled receptors, CB1 and CB2 receptor activation leads to an 
inhibition of adenylate cyclase activity and subsequent inhibition of cyclic adenosine 
monophosphate (cAMP) accumulation. Additionally, cannabinoid receptor activation induces 
MAPK signaling pathways like ERK and FAK (focal adhesion kinase) in the case of CB1 
receptor activation and ERK1/2 and p38 in the case of CB2 receptor activation (Piomelli, 
2003; Beltramo, 2009). 
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Figure 2 The endocannabinoid system. Plant-derived cannabinoids like Δ
9
-
tetrahydrocannabinol (Δ
9
-THC) and endogenous cannabinoids like AEA and 2-AG bind to cannabinoid 
receptors 1 and 2 on neurons and immune cells (not depicted here). Both endogenous cannabinoids 
are produced after an increase in intracellular Ca
2+
 in postsynaptic neurons. As retrograde 
messengers, endocannabinoids travel to presynaptically expressed cannabinoid receptors to activate 
them. Activation of cannabinoid receptors leads to an inhibition of voltage-gated Ca
2+
 channels and 
the activation of K
+
 channels. The depolarization of the presynaptic neuron is thereby diminished and 
consequently also the release of neurotransmitter. After clearance of endocannabinoids from the 
synaptic cleft, they are degraded by fatty acid amide hydrolase or monoacylglycerol to arachidonic 
acid and ethanolamine (not depicted here). - With permission from Macmillan Publishers Ltd: Nature 
Reviews Cancer, Volume 12, Guillermo Velasco, Cristina Sánchez and Manuel Guzman, Towards the 
use of cannabinoids as antitumour agents, 436-444, Copyright (2012). 
 
 
Endocannabinoid signaling is terminated by the endocannabinoid degrading enzymes 
monoacylglycerol (MAGL) and fatty acid amide hydrolase (FAAH) (Piomelli, 2003). 
Due to its central expression, CB1 receptor activation accounts for the psychomimetic 
side effects of cannabinoid ligands like Δ9-THC on cognition, motor activity and memory 
(Wilson and Nicoll, 2002). The four major behavioral effects of cannabinoid intoxication, 
hypomotility, catalepsy on a ring, hypothermia and anti-nociception, are measured in the 
tetrad test (Martin et al., 1991).  
In marked contrast, activation of CB2 receptors alone is devoid of psychomimetic side 
effects, while it similarly produces strong anti-nociceptive and anti-inflammatory effects under 
pathological conditions (Kinsey et al., 2011; Rahn et al., 2011). 
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1.5 The endocannabinoid system and pain 
The analgesic properties of cannabis preparations are known since antiquity and were 
used in the treatment of various pain conditions (Zias et al., 1993). Recently, the 
endocannabinoid system came again into the focus for the treatment of pain. The localization 
of its receptors on peripheral nociceptive neurons and in several brain regions involved in 
pain signaling (Sañudo-Peña et al., 1999), as well as on immune cells (Maresz et al., 2005) 
made it an attractive therapeutic target. Clinical trials have already demonstrated beneficial 
effects of cannabis extracts and synthetic Δ9-THC preparations in pain patients. Some of 
these substances have already been approved in selected countries for clinical pain 
management at doses and formulations that show only minor central side effects (Ben Amar, 
2006; Iskedjian et al., 2007; Karst and Wippermann, 2009; Lynch and Campbell, 2011). 
Nevertheless, the potential for psychomimetic effects of Δ9-THC containing medications is an 
important consideration that limits their clinical use. Thus, several approaches were exploited 
to decrease psychomimetic side effects in cannabinoid-based therapies: 
Firstly, peripherally restricted cannabinoid agonists that only marginally cross the blood-
brain-barrier were developed to circumvent central CB1 receptor activation. These 
compounds were shown to similarly exert anti-hyperalgesic effects in animal models of pain 
than common cannabinoid ligands (Dyson et al., 2005; Dziadulewicz et al., 2007; Wei et al., 
2012). Secondly, inhibitors of the endocannabinoid degrading enzymes FAAH and MAGL 
were used to increase the endocannabinoid tone and thereby induce anti-nociception with no 
or minimal psychomimetic side effects (Jhaveri et al., 2006; Kinsey et al., 2009; Clapper et 
al., 2010; Schlosburg et al., 2010). Both approaches still do not fully exclude the risk of 
central mediated side effect. Finally, effort was put on the identification of selective agonists 
for the peripheral CB2 receptor, which completely lacks the liability of potential 
psychomimetic side effects. Indeed, reports that synthetic CB2 receptor agonists produce 
anti-nociceptive effects in animal models of acute and chronic pain are rising. Synthetic CB2 
agonists like JWH-133, AM1241 and GW405833 among several others were shown to exert 
beneficial effects on both mechanical allodynia and thermal hyperalgesia in animal models of 
inflammatory and neuropathic pain. The specificity of these effects for CB2 receptors was 
confirmed with the use of CB2 receptor antagonists like SR144528 and AM630 (Guindon and 
Hohmann, 2008; Beltramo, 2009).  
It has been also shown that CB2 receptor expression is up regulated in dorsal root ganglia 
and spinal cord tissue under neuropathic pain conditions, paralleling the activation of glia 
cells (Zhang et al., 2003; Hsieh et al., 2011). Activation of CB2 receptors in turn attenuates 
glia responses in the dorsal horn of the spinal cord (Romero Sandoval and Eisenach, 2007, 
Luongo et al., 2010 Leichsenring et al., 2009), which supports a immunomodulatory role of 
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CB2 receptors in pain. The use of genetically modified mice (Buckley et al., 2000; Rácz et 
al., 2008b) gave further insights into the role of CB2 receptors during the development of 
neuropathic pain. Thus, constitutive CB2 knockout mice with a partial ligation of the sciatic 
nerve exhibited pain not only in the ipsilateral paw, but also developed a mirror image of pain 
in the contralateral paw. This was accompanied by an exaggerated microglia and astrocyte 
response in the dorsal horn, spreading from the ipsilateral side to the contralateral side. Mice 
overexpressing the CB2 receptor in contrast showed a decreased manifestation of 
neuropathic pain (Rácz et al., 2008b). Consequently, evidence is growing that CB2 receptors 
are crucial mediators in the control of inflammatory responses during pathological pain. The 
same authors found that interferon-γ, expressed by neurons and astrocytes, is critically 
involved in this process, as CB2/interferon-γ double knockout mice lacked the mirror image 
of pain found in the CB2 knockout mice. The authors stated that CB2 receptor activation 
possibly diminishes the interferon-γ-induced neuroinflammatory processes, involving iNOS 
and chemokine receptor 2 expression in microglia (Rácz et al., 2008a).  
Given the anti-nociceptive and immunomodulatory properties of CB2 receptors and their 
mainly peripheral distribution, they clearly form a promising target for the development of 
new drugs in the treatment of neuropathic pain. 
 
1.6 The plant volatile β-caryophyllene 
Some of the most widespread medicines, recreational drugs or poisons, most of them 
belonging to the group of alkaloids, are secondary metabolites from plants: morphine, 
nicotine, caffeine, cocaine, quinine, atropine, strychnine, cardiac glycosides, paclitaxel and 
Δ9-THC among many others (Lüttge et al., 2005). However, beside these compounds with 
obvious pharmacological activity, evidence is rising that also secondary metabolites, which 
are so far mainly known for their aromatic or chromophore properties, are pharmacologically 
interesting (Kris-Etherton et al., 2002; Tapsell et al., 2006). Cannabis sativa L. plants are a 
rich source for such plant metabolites. Besides the well-known Δ9-THC, the essential oil of 
cannabis comprises a variety of around 400 other secondary plant metabolites, including 
over 65 other cannabinoid-like components (Gertsch et al., 2008). So far, only three classical 
cannabinoids with a terpenophelic structure have been shown to directly act on CB1 or CB2 
receptors (Pertwee, 2008), while other, structurally different metabolites (referred to as 
“phytocannabinoids”) were also shown to act on the endocannabinoid system, e.g. fatty acid 
derivatives and polyphenols (Gertsch et al., 2010). Still, there might be a variety of 
unexplored phytocannabinoids with therapeutic potential present in the essential oils of 
cannabis or other metabolite-rich plants. Indeed, it was found that the essential oil of 
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cannabis lacking the classical cannabinoids still presented cannabinoid receptor binding. 
Screening of the isolated constituents identified the sesquiterpene β-caryophyllene (BCP; 
see Figure 3) as the first natural, selective agonist for CB2 receptors with Ki values of the 
(E)-BCP isomer in the nM range (Ki = 155 + 4 nM). The (Z)-BCP isomer also showed a slight 
binding affinity (Ki = 485 + 36 nM), while the oxidation product BCP oxide and the opened-
ring isomer α-humulene did not show binding affinities to CB2 receptors (Gertsch et al., 
2008). Besides its occurrence in cannabis, BCP is among the most widespread plant 
volatiles and is also found in large amounts in the essential oils of different spice and food 
plants, such as oregano (Origanum vulgare L.), cinnamon (Cinnamomum spp.), clove 
(Syzygium aromaticum), rosemary (Rosmarinus officinalis L.), thyme (Thymus serpyllum) 
and black pepper (Piper nigrum L.) among many others (Zheng et al., 1992; Mockute et al., 
2001; Hudaib et al., 2002; Jayaprakasha et al., 2003; Orav et al., 2004; Bernardes et al., 
2010). Thus, it represents a novel dietary phytocannabinoid. BCP and related 
sesquiterpenes have insecticidal and anti-viral properties, and constitute part of the plant 
defense system against pathogens (Dunkić et al., 2011; Maffei et al., 2011; Huang et al., 
2012). Due to its weak aromatic taste, it is also commercially used as a food additive 
(Gertsch et al., 2008). As such, it is approved by several independent agencies with no 
known toxicity (US Food and Drug Administration (FDA), US Flavor and Extract 
Manufacturers Association (FEMA), Joint FAO/WHO Expert Committee on Food Additives 
(JECFA)). Several health effects have been attributed to BCP or plants containing BCP, 
including anti-inflammatory (Gertsch et al., 2008), local anaesthetic (Ghelardini et al., 2001) 
and anti-carcinogenic (Legault and Pichette, 2007; Di Sotto et al., 2010) activity. The natural 
source of BCP makes it surely an interesting compound, also for the treatment of chronic 
pain conditions. 
 
 
Figure 3 Chemical structure of the sesquiterpene BCP isomers: (E)-BCP and (Z)-BCP, 
their oxidation product BCP oxide and the opened-ring isomer α-humulene. From ©Gertsch et al., 
2008 (PNAS). 
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1.7 Aims of the study 
The recent years of research clearly indicated that the endocannabinoid system is 
critically involved in the modulation of chronic pain. However, cannabinoid-based therapies 
are so far often associated with central-mediated, adverse side effects and therefore 
constrain their therapeutic use. The plant volatile BCP was identified as the first natural, 
selective CB2 receptor agonist, which lacks the potential of side effects due to its mainly 
peripheral-located target. Earlier studies also verified its anti-inflammatory properties. 
Because there is especially a need for the evaluation of new and effective drugs for the 
treatment of neuropathic pain, one aim of this study was to evaluate the potential of BCP to 
exert anti-nociceptive effects in a model of neuropathic pain. Here, a mouse model of partial 
nerve ligation-induced neuropathic pain was used and the development of mechanical 
allodynia and thermal hyperalgesia after chronic treatment with different doses of BCP was 
analyzed. To exclude that BCP produces similar psychoactive side effects known from CB1 
receptor agonists, the cannabinoid tetrad test was performed.  
It is known that the appearance of activated glia cells in the spinal cord is associated with 
the occurrence of pain. Therefore, a further purpose of the study was to investigate the effect 
of BCP on the activation of glia cells in the spinal cord by immunohistochemistry. To get 
insights into signaling pathways possibly involved in chronic pain modulation by BCP, 
quantitative real-time PCR for several candidate molecules was performed. 
In the next part of the study a second animal model for neuropathic pain was established. 
It is known that chemotherapeutic agents like cisplatin, vincristine or paclitaxel induce 
neuropathic pain symptoms in cancer patients. The mechanisms underlying the development 
of chemotherapeutic drug-induced neuropathic pain differ from those in traumatic nerve 
injury models. Therefore, a further aim of the study was to investigate the role of CB2 
receptors in this neuropathic pain model. For the establishment of chemotherapeutic drug-
induced neuropathic pain mice received injections of paclitaxel and the development of 
mechanical allodynia, thermal hyperalgesia and cold allodynia was measured in wild type 
and CB2 receptor knockout mice. 
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2 MATERIAL 
2.1 Equipment 
Equipment Company 
Open field arena TSE Systems 
Balance  BP 121S, Sartorius 
Camera AxioCam MRm, Zeiss 
Catalepsy ring In-house workshop 
Centrifuges  Galaxy mini, VWR 
 Biofuge fresco, Heraeus 
 Multifuge 2 S-R, Heraeus 
Cryostate CM3050S, Leica 
Vaporizer for isofluorane ISOFLO, Eickmeyer 
Hargreaves’ apparatus Ugo Basile 
Hot/Cold plate Ugo Basile 
Incubator BE-ED-FD, Binder 
Magnetic stirrer MR 3001K, Heidolph 
Microscope Axioplan 2, Zeiss  
 Imager M2, Zeiss 
PCR machine iCycler, Bio-Rad Laboratories 
pH-Meter pH 515i, WTW 
Rectal thermometer 
Portable Thermometer BAT-12, Harvard 
Apparatus 
Animal shaver Isis GT420, Aesculap 
Spectral photometer 91-ND-1000 UV/Vis, Nanodrop 
Tail flick analgesia meter Columbus Instruments, OH., USA 
Fast real-time PCR system  7900HT, Applied Biosystems 
Vortexer Vortex Genie 2, Scientific Industries 
Von Frey apparatus Ugo Basile 
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2.1 Chemicals and Reagents 
Substance Company 
0,9 % Saline Braun 
0.1 M DTT Life Technologies 
10 mM dNTP Mix Life Technologies 
5 x First Strand buffer Life Technologies 
Betaisodona Mundipharma 
Bromochloropropanol Sigma-Aldrich 
Bovine serum albumin PAA 
Cooling spray Roth 
Cremophor Sigma-Aldrich 
DABCO Roth 
Diethyl pyrocarbonate (DEPC) Sigma-Aldrich 
Ethanol VWR 
Fluoromount G SouthernBiotech 
Glycerol Sigma-Aldrich 
Guanidine HCL Sigma-Aldrich 
Hydrochloric acid Sigma-Aldrich 
Isofluorane Abott GmbH 
Isopentane Sigma-Aldrich 
Isopropyl alcohol Roth/VWR 
Mowiol Roth 
OCT Compound Sakura Finetek 
Oligo(dT)12-18 Primer Life Technologies  
Olive oil Sigma-Aldrich 
Oxygen Linde 
PapPen Vector Laboratories 
Paraformaldehyd Sigma-Aldrich 
PBS tablets Life Technologies 
RNase free water Life Technologies 
RNAse OFF Applichem 
SDS Sigma-Aldrich 
Sodium hydroxide Sigma-Aldrich 
Superscript II Reverse 
Transcriptase Life Technologies 
TRIS-HCL Roth 
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Tocrisolve 100 Tocris 
Triton X-100 Sigma-Aldrich 
Trizol Life Technology 
  
2.2 Solutions 
2.2.1 Histological experiments 
PFA/PBS solution 
Paraformaldehyde         4 % (w/v) 
PBS 
 
Sucrose 
Sucrose           10 % (w/v) 
          or  20 % (w/v) 
PBS 
 
Permeabilization solution 
Triton X-100          0.5 % (v/v) 
PBS 
 
Blocking solution 
Normal donkey serum        10 % (v/v) 
Bovine serum albumin (BSA)       3 % (w/v) 
PBS 
 
Mowiol – embedding medium 
Mowiol 4-88          9 % (w/v) 
Glycerol          22 % (w/v) 
DABCO          2.4 % (w/v) 
TRIS-HCl          0.1 M 
Distilled water 
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2.2.2 Biomolecular experiments 
Ethanol 
Ethanol          75 % (v/v) 
RNase free water 
 
DEPC water 
DEPC           0.1 % (v/v) 
RNase free water 
2.3 Software 
Software   Company 
ActiMot   TSE Systems 
AxioVision   Carl Zeiss, Version 4.8.0.0 
Image J    by Wayne Rasband, Version 1.42q 
Office 2008   Microsoft Corporation 
Prism 4   GraphPad Software, Inc, Version 4.0a (2003) 
SDS 2.2   Applied Biosystems 
Statistika   StatSoft, Inc., Version 7.1 (2005) 
 
2.4 Drugs 
Drug    Vehicle  Doses (mg/kg) Company 
β-caryophyllene (BCP) Olive oil   0.1, 1, 5, 10  provided by Jürg 
Gertsch (Institute of Biochemistry and Molecular Medicine, University of Bern, Switzerland) 
JWH-133   Tocrisolve 100  1, 5   Tocris  
Δ9-THC    Cremophor, Saline  5, 10    THC Pharm 
Paclitaxel   Saline (0.9%)    4   HEXAL 
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2.5 Antibodies 
Antigen  Species  Fluorochrome  Company 
Antibodies 
GFAP   goat   -   Santa Cruz 
Iba1   rabbit   -   Wako 
goat IgG  donkey  Alexa 488  Life Technologies 
goat IgG  donkey  Cy3   Life Technologies 
rabbit IgG  donkey  Alexa 488  Life Technologies 
 
Antiserum 
donkey IgG        Sigma-Aldrich 
 
2.6 Gene expression assays 
All gene expression assays and the gene expression master mix used in the experiments 
were purchased from Applied Biosystems (Life Technologies). Following assays were used: 
 
 
Target gene        ID 
Actb   beta-actin      Mm01205647_g1 
Igtp   interferon gamma induced GTPase   Mm00497611_m1 
Tgtp1   T-cell specific GTPase 1    Mm01295120_m1 
Cnr2   cannabinoid receptor 2    Mm00438286_m1 
Nos2   inducible nitric oxide synthase 2   Mm00440502_m1 
IL-1β  interleukin-1β      Mm01336189_m1 
 
2.7 Mouse strains 
Wild type and CB2 knock-out mice on a C57BL/6J background were used. Mice with a 
genetic deletion of the CB2 receptor have been described previously (Buckley et al., 2000). 
Mutant mice were crossed for more than 10 generations to C57BL/6J mice and thus are 
considered to be congenic for this background.  
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3 METHODS 
3.1 Behavioral experiments 
Animal husbandry and all behavioral experiments took place in the S1 (Sicherheitsstufe 1, 
§§ 4-7 GenTSV) animal facility of the university clinics in Bonn („Haus für experimentelle 
Therapy”, HET). Experimental procedures complied with all regulations for animal 
experimentation in Germany and were approved by local authorities (Landesamt für Natur, 
Umwelt und Verbraucherschutz NRW; AZ: 9.93.2.10.35.07.310 and 87-51.04.2010.A393). 
3.1.1 Animals 
For the neuropathic pain experiments 12 to 16 weeks old, for the cannabinoid tetrad nine 
to ten weeks old male and female mice were used. Mice were either taken from breeding 
colonies of our own animal facility or purchased from Charles River Laboratories 
(Wilmington, MA, USA). Mice were housed in groups of three to five mice per cage under 
controlled illumination (light-dark cycle: 12:12 h) and environmental conditions (temperature: 
22 ± 2 °C; humidity: 55 ± 5 %). All mice had free access to water and food pellets. 
Mice, treated with paclitaxel, were cleaned separately and the bedding was disposed of as 
cytotoxic waste. 
3.1.2 Experimental design 
3.1.2.1 Partial nerve ligation and BCP treatment 
All experiments were performed using the following protocol: Mice were habituated to the 
experimental setup for > 1h during three consecutive days. After habituation, baseline 
behavioral measurements were conducted. One day later the partial nerve ligation was 
performed. On the next day the daily BCP, JWH-133 or vehicle treatment started for a period 
of two weeks (see also 3.1.3). To assess the development of pain and the effect of 
treatment, mice were regularly tested in the behavioral tests (von Frey test, 3.1.6; 
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Hargreaves’ test, 3.1.7) on day 3, 6, 8, 10 and 14 after the partial nerve ligation (Figure 4). 
On the test-days drugs were administered after finishing the experiments. 
 
 
 
Figure 4  Time schedule of the BCP experiments. BCP treatment started one day after the 
surgery (OP). The following behavioral tests (von Frey test and Hargreaves’ test) were conducted at 
day 3, 6, 8, 10 and 14. 
 
 
 
3.1.2.2 Paclitaxel-induced neuropathic pain model 
Habituation and baseline measurements were performed as described above. After 
baseline measurements the first paclitaxel injection was administered to CB2 knock-out and 
wild type mice. Behavioral measurements (von Frey test, 3.1.6; Hargreaves’ test, 3.1.7; Cold 
plate test, 3.1.8) were performed on days 4, 7, 11, 15 and 22 after the first injection (Figure 
5).  
 
 
Figure 5  Time schedule of the paclitaxel experiments. First paclitaxel injection was 
administered one day after the basal measurements followed by injections on day 2, 4 and 6 after the 
first injection. Behavioral tests (von Frey test, Hargreaves’ test and Cold plate test) were conducted at 
day 3, 6, 8, 10 and 14. 
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3.1.3 Cannabinoid treatment 
Concentrated BCP (5:1 isomer mixture of (E)- and (Z)-BCP; purified from a commercially 
available 70 % pure preparation (TCI) by HPLC and analysis in GC/MS) was kindly provided 
by Jürg Gertsch. BCP (95 % purity) contained residual amounts of α-humulene and the BCP 
oxidation product BCP-oxide (see Figure 3). The BCP stock solution was dissolved in olive 
oil (Sigma-Aldrich) at a concentration of 0.02, 0.2, 1 and 2 mg/ml and frozen in 2 ml aliquots 
at -20 °C. Aliquots were defrosted on each treatment day and administered by gavage at a 
volume of 5 ml/kg with the help of a feeding‐needle, thus resulting in doses of 0.1, 1, 5 or 
10 mg/kg respectively.  
JWH-133 was dissolved in Tocrisolve 100 (both Tocris Bioscience) at a concentration of 
0.1 and 0.5 mg/ml and mice received subcutaneous injections in a volume of 10 ml/kg, thus 
resulting in doses of 1 and 5 mg/kg.  
Δ9-THC, in a stock solution with ethanol (THC Pharm), was dissolved in Cremophor 
(Sigma-Aldrich) in a 1:1 mixture prior to dilution with saline to reach a final mixture of 1:1:18 
at a Δ9-THC-concentration of 0.5 and 1 mg/ml. Mice received intraperitoneal (i.p.) injections 
in a volume of 10 ml/kg, thus resulting in doss of 5 and 10 mg/kg. 
3.1.4 Partial sciatic nerve ligation 
A partial ligation of the right sciatic nerve was performed to induce neuropathic pain. The 
partial nerve ligation (PNL) model is a reliable model to investigate neuropathic pain and was 
first described in mice by Malmberg and Basbaum (1998). Briefly, mice were initially 
anesthetized in a box with an oxygen/isoflurane mixture (2 – 2.5 % in 95 % O2), fixed on the 
surgery table and kept under a constant stream of isoflurane (1,5 – 2 % in 95 % O2) to 
maintain anesthesia. The right thigh and hip were shaved and disinfected with betaisodona 
(Mundipharma GmbH). After a small incision to the skin using a scalpel the underlying 
muscle was punctured with sharp scissors and the sciatic nerve exposed with thin tweezers. 
One half to one third of the nerve was ligated with a medical polypropylene thread (9-0). In 
sham-operated mice the nerve was exposed, but not ligated. Finally, muscle and skin were 
tightly sutured with polypropylene threads (7-0; 5-0) and the lesion site disinfected. 
3.1.5 Paclitaxel-induced neuropathic pain 
Smith et al. (2004) introduced the paclitaxel-induced neuropathic pain model for mice. 
Paclitaxel produces a robust bilateral neuropathy without the need of an invasive surgery. To 
establish this model and to study gene effects between CB2 knock-out and wild type mice, 
the protocol of Smith et al. (2004) was slightly adjusted: On each injection day, paclitaxel 
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(HEXAL) was freshly diluted in physiological saline to a final concentration of 0.4 mg/ml. Four 
injections of 4 mg/kg paclitaxel were administered i.p. on alternating successive days (days 
0, 2, 4 and 6) to induce neuropathic pain. On day 4, on which also behavioral measurements 
were conducted, paclitaxel was administered after finishing the experiments to avoid 
behavioral disturbances in the tests. All equipment used in direct contact with paclitaxel, 
solutions and paclitaxel stock solutions were disposed of as cytotoxic waste. 
3.1.6 Von Frey test 
Mice developing neuropathic pain present an increased sensitivity towards normally non-
noxious mechanical stimuli (allodynia) (Costigan et al., 2009). This mechanical allodynia was 
assessed with a dynamic plantar aesthesiometer (Figure 6, Ugo Basile Biological Research 
Apparatus; maximum force: 15 g, ramp: 20 s). It consists of an electronically controlled 
mobile pressure-actuator that is able to exert a continuously increasing force.  
Individual mice were placed in elevated transparent Plexiglas chambers (9 x 9 x 13 cm) 
with a metal mesh floor. After cessation of exploratory behavior (≤ 1h), experiments were 
started. The metal filament of the actuator (diameter: 0,5 mm) was applied to the middle of 
the plantar surface of the hind paw and automatically lifted with increasing force until a clear 
withdrawal response of the ipsilateral or contralateral hind paw was triggered. The withdrawal 
responses were automatically recorded and given as the withdrawal-triggering force in 
grams. Measurements were repeated three times for each paw, separated by > 3 min to 
avoid habituation, and means were calculated. Mice were not tested while being very active 
or sleeping. Testing chambers were cleaned with a 70 % ethanol solution between mice. 
3.1.7 Hargreaves’ test 
Neuropathic pain also induces diminished withdrawal thresholds towards noxious heat 
stimuli (thermal hyperalgesia) (Costigan et al., 2009). This thermal hyperalgesia was 
evaluated using a Hargreaves’ apparatus with a mobile I.R. (infrared) heat source (Figure 6, 
Ugo Basile Biological Research Apparatus, I.R. intensity: 40).  
Mice were placed in elevated transparent Plexiglas chambers (10 x 10 x 13 cm) with glass 
floor. After cessation of exploratory behavior (≤ 1 h), the experiments were started. The 
radiant I.R. source of the apparatus was placed under the plantar surface of the hind paws 
and the heat stimuli activated. A clear withdrawal, shaking or licking reaction of the mice 
switched off the I.R. source and the apparatus automatically displayed the withdrawal latency 
in seconds. Mean withdrawal latencies were determined by averaging three to five trials 
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separated by > 5 min to avoid habituation. Mice were not tested if they were very active or 
sleeping. Testing chambers were cleaned with a 70 % ethanol solution between mice.  
Von Frey test and Hargreaves’ test were performed with the same group of mice, with 
a minimum intertest interval of 1 hour.  
3.1.8 Cold plate test 
The Cold plate test was used to measure cold allodynia, which is also frequently observed 
in mice suffering from neuropathic pain (Choi et al., 1994). For this test a commercially 
available Hot/Cold plate apparatus (Figure 6, Ugo Basile) was used. It consists of a round 
plate surrounded by a cylindrical Plexiglas restrainer. The temperature of the plate is 
adjustable and was maintained at 5 ± 1 °C for cold allodynia measurement. Individual mice 
were placed on the plate and the mean number of right and left hind paw elevations was 
assessed during 5 min. The Cold plate was cleaned with a 70 % ethanol solution between 
mice. The Cold plate test and von Frey test were performed with the same group of mice, 
with a minimum intertest interval of 1 hour. 
 
 
Figure 6 Experimental set ups for behavioral measurements. Mice were tested in the 
von Frey test (left panel), Hargreaves’ test (middle panel) and on a Cold plate (right panel). 
3.1.9 Tetrad test 
To exclude that BCP produces the psychoactive side effects known from CB1 receptor 
activation (Martin et al., 1991), the tetrad test was performed. Motor activity in the open field, 
immobility (catalepsy) on a ring, anti-nociception in the tail flick test and rectal temperature 
were measured 45 min after an acute oral administration of BCP in different doses (1 mg/kg 
and 10 mg/kg) or vehicle (olive oil), as well as after an i.p. injection of Δ9-THC (5 mg/kg) as 
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positive control. To similarly measure peak cannabinoid-induced effects, other groups of 
control mice were injected i.p. with a dose of 10 mg/kg Δ9-THC or vehicle 
(ethanol/Cremophor/saline) and were tested 20 min after the injection (peak of i.p. Δ9-THC 
metabolism). All drug solutions were freshly prepared before the experiments. An additional 
observer, who was unaware of the treatments, assisted to record the test values. 
3.1.9.1 Open-field test 
To evaluate locomotor activity, mice were placed individually in the center of an open-field 
arena (45 x 45 x 23 cm) in a dark and soundproof room. An automatic monitoring system 
with an infrared light beam frame surrounding the arena (ActiMot, TSE Systems, Bad 
Homburg, Germany) tracked the light beam breaks (XY location) of the mice during 10 min. 
The motor activity was then evaluated by calculating the total distance that the mice travelled 
during that time. The testing arena was cleaned with a 70 % ethanol solution between mice. 
3.1.9.2 Catalepsy 
Mice were placed on a vertical tube (diameter: 5.5 cm; height: 16 cm). The time that the 
mice remained immobile during the 5 min observation period was recorded. Mice that fell 
down or jumped off the ring were immediately placed back on the ring. One animal was 
excluded from the experiments after five jumps off the ring. 
3.1.9.3 Tail flick test 
The tail flick latencies were determined with a tail-flick apparatus (Columbus Instruments, 
OH., USA). Mice were manually restraint and the tail was placed over a radiant I.R. heat 
source. The latency until mice withdrew their tail was measured. The I.R. intensity was 
adjusted so that the mean tail withdrawal latency was around 4-5 s. The cut-off time was set 
at 12 s to prevent tissue damage. 
3.1.9.4 Rectal temperature 
Body temperature of mice was measured using a rectal thermometer. Temperatures were 
recorded immediately and 1 h after the administration of BCP (1 and 10 mg/kg), Δ9-THC 
(5 mg/kg) or olive oil. The groups receiving 10 mg/kg Δ9-THC and Cremophor were 
measured 35 minutes after administration, according to the earlier start of behavioral 
measurements. Data are expressed as the change in body temperature (ΔT = T after 
treatment – T before treatment). 
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3.1.10 Statistical analysis of behavioral data 
For all data mean values and the standard error of the mean (SEM) were calculated. 
Statistical analyses were carried out using Statistika 7.1 (StatSoft Inc.). If not stated 
otherwise, differences between groups in the behavioral experiments were analyzed by 
repeated measures analysis of variance (ANOVA). The categorical factors side (ipsilateral 
side vs. contralateral side), surgery (sham mice vs. PNL mice) and treatment (drug-treated 
mice vs. vehicle-treated mice) were analyzed and time was used as within-effect. Significant 
interactions in the repeated measures ANOVA were followed by Fisher's Least Significant 
Difference (Fisher-LSD) post hoc test.  
Results of the cannabinoid tetrad were analyzed by one-way ANOVA or repeated 
measures ANOVA (body temperature) using treatment as main factor.  
The level of significance was set at p ≤ 0.05.  
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3.2 Histological experiments 
3.2.1 Tissue preparation 
At the end of the behavioral experiments mice were sacrificed by cervical dislocation. The 
lumbar region of the spine was cut off and the spinal cord was flushed out with the help of a 
syringe filled with 0.9 % physiological saline solution. The tissue samples were quickly frozen 
in isopentane on dry ice. 
To improve microglia staining we performed a second IHC series using pre-fixed tissues. 
Therefore, mice were anesthetized using a Ketavet/Rompun mixture (10 mg/kg / 0.1 mg/kg) 
and were intracardially perfused with phosphate buffered saline (PBS) on dry ice for 5 min 
followed by 4 % paraformaldehyde (PFA) solution for 10 min. Subsequently the spinal cord 
was harvested as described before and kept in 10 % saccharose solution overnight. Next, 
the tissue samples were transferred to 20 % saccharose solution for 24 h and finally shock-
frozen in isopentane on dry ice.  
All tissue samples were stored at -80 °C until further use. 
3.2.2 Preparation of tissue sections 
The lumbar part from L4 to L6 of the spinal cord was selected, embedded in O.C.T. 
compound (Tissue Tek®, Sakura) and quickly cooled down with cooling spray (Roth) to 
prevent thawing.  
For the non-perfused tissue 12 μm thick, transversal sections were prepared on a cryostat 
(Leica CM 3050; Leica Microsystems) at -20 °C. Tissue of one mouse per treatment group 
with four to six sections each mouse was mounted on Star frost-coated slides.  
For the perfused tissue 16 μm thick, transversal sections were prepared at -18 °C. Tissue 
of one mouse per treatment group with six sections each mouse was mounted on Star frost-
coated slides.  
Sections were dried on a heating plate and finally stored at -80 ° C. 
3.2.3 Immunofluorescent staining 
Frozen slides were put on a heating plate at 38 °C for drying (30 min) and the sections 
were surrounded with a hydrophobic barrier with a PapPen. All steps were performed at 
room temperature unless otherwise stated. 
Two series of immunohistochemistry (IHC) were performed. In the first IHC series 
cryosections of non-perfused tissue were used. Here, the sections were fixed for 20 min in 
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4 % PFA solution, and washed three times for 10 min in PBS. For permeabilization, sections 
were incubated in 0.5 % Triton X-100 (Sigma-Aldrich) for 1 h. After three further washing 
steps a blocking solution containing 3 % BSA (PAA) and 10 % donkey serum (Abcam) in 
PBS was applied and the sections were incubated in a humid chamber for 2 h. After removal 
of the blocking solution the sections were incubated with polyclonal primary antibody against 
astrocytic glial fibrillary acidic protein (GFAP, goat polyclonal, 1:500, Santa Cruz 
Biotechnology) at 4 °C overnight. On the next day, the sections were kept at 37 °C in an 
incubator for 2 h. After removal of the antibody solution the sections were washed three 
times in PBS, shortly placed in 0.5 % BSA in PBS and incubated with green fluorescent 
Alexa Fluor 488 anti-goat secondary antibody (Life Technologies). The slices were mounted 
with Fluoromount G (Southern Biotech) and fixed with nail polish to prevent drying of the 
mounting fluid. 
To improve our staining strategy for the microglia staining a second IHC series with 
cyrosections of perfused tissue was performed. The tissue sections were shortly placed in 
PBS and incubated in 0.5 % Triton X-100 (Sigma-Aldrich) for 1 h to permeabilize the cell 
membranes. After three washing steps a blocking solution containing 3 % BSA and 10 % 
donkey serum in PBS was applied and the sections were incubated in a humid chamber for 
2 h. After removal of the blocking solution, the sections were incubated with a primary 
antibody against astrocytic GFAP (goat polyclonal, 1:500, Santa Cruz Biotechnology) and 
microglial ionized calcium-binding adapter molecule 1 (Iba1, rabbit polyclonal, 1:1000, Wako) 
at 4 °C for 42 h. On the second staining day the sections were put at 37 °C in an incubator 
for 2 h. After removal of the antibody solution, the sections were washed three times in PBS, 
shortly placed in 0.5 % BSA in PBS and incubated with red fluorescent Cy3 anti-goat 
secondary antibody (1:1000, Jackson ImmunoReasearch) and green fluorescent Alexa Fluor 
488 anti-rabbit secondary antibody (1:1000, Life Technologies). The slices were mounted 
with Mowiol 4-88 (Roth). 
3.2.4 Image acquisition 
For the first IHC series (non-perfused tissue) images were acquired using a Zeiss 
Axioplan 2 fluorescent microscope (Carl Zeiss Microimaging). Images of GFAP-stained 
ipsilateral and contralateral dorsal horns were taken with a 40x, 1.3 NA oil-immersion 
objective and constant exposure time (340 ms) and settings (80 %) for quantitative analysis. 
Representative images were taken with a 20x, and a 40x 1.3 NA oil-immersion objective. All 
images were taken with the same exposure time (representative pictures: 370 and 200 ms) 
and settings (intensity: 80 %). 
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For the second IHC series (perfused tissue) pictures were acquired using a Zeiss Imager 
M2 fluorescent microscope (Carl Zeiss Microimaging), which was newly installed in the 
laboratory. Therefore, images of the Iba1 and GFAP double-stained, spinal cord sections 
were taken this time with the multichannel mosaic function of the new AxioVision software 
(Carl Zeiss Microimaging) at 20x magnification (constant exposure time, Iba1: 430 ms, 
GFAP: 170 ms; intensity: 80 %). The mosaics were converted to one image before 
quantitative analysis. To improve the overlay of the mosaic images the “stitching” function of 
the software was used for representative pictures, which correctly aligns the single images to 
each other. 
3.2.5 Semiquantitative analysis of glia staining 
The method of Romero-Sandoval and Eisenach (2007) was modified to evaluate 
microgliosis and astrogliosis after peripheral nerve injury. Here, an increase in fluorescent 
GFAP or Iba1 signals above a defined intensity threshold is interpreted as an increase in cell 
numbers (proliferation) and is therefore a sign for glial activation. A change in morphology 
(hypertrophy, retracted and thickened processes) can also lead to an increase in fluorescent 
signal. 
In the first IHC series (non-perfused tissue) whole images of ipsilateral or contralateral 
dorsal horns (40x magnification) of three mice per treatment group were analyzed. Using a 
macro routine in Image-J 1.42q (NIH) the pictures were pre-processed before the analysis to 
scale (conversion of pixel to micrometer) and sharpen the images. Afterwards the color was 
inverted to facilitate the subsequent analysis. In a second macro the stained area whose 
intensity lay above a defined intensity threshold was compared to whole image area (percent 
stained area). Data were expressed as the difference between the signals in the ipsilateral 
compared to the contralateral side (percent stained area ipsilateral side - percent stained 
area contralateral side) to normalize data. 
In the second IHC series (perfused tissue) ipsilateral or contralateral dorsal horns (20x 
magnification) of four to five mice per treatment group were analyzed using a similar macro 
routine in Image-J 1.42q (NIH) as in the first staining series. Due to the different image 
acquisition (mosaic function, see also 3.2.4) with the new microscope, here an observer blind 
to the experimental groups manually surrounded the dorsal horns to define the region of 
interest. The pictures were pre-processed before analysis to scale (conversion of pixel to 
micrometer) and sharpen the pictures as well as invert the color. The stained area whose 
intensity lay above a defined intensity threshold was compared to whole region of interest 
(percent stained area; see also Figure 7). Data were expressed as the difference between 
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the signals in the ipsilateral compared to the contralateral side (percent stained area 
ipsilateral side - percent stained area contralateral side) to normalize data. 
 
 
 
Figure 7 Example for quantitative analysis with ImageJ. The ipsilateral and contralateral 
dorsal horns were manually surrounded (left panel) and the colors of the image were inverted (middle 
panel). The area of stained signals, which lay above the pre-defined threshold (here marked as red 
dots in the dorsal horns; right panel) was measured. 
 
3.2.6 Statistical analysis of histological data 
For the analysis of histological data the Mann-Whitney-U test was performed. The level of 
significance was set at p ≤ 0.05. 
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3.3 Biomolecular experiments 
3.3.1 Tissue preparation 
Mice were sacrificed by cervical dislocation and the lumbar region of the spine was cut off. 
The spinal cord was flushed out with the help of a syringe filled with 0.9 % physiological 
saline solution and maintained on ice while ipsilateral and contralateral sides were carefully 
separated with a scalpel. The tissue samples were quickly frozen in isopentane on dry ice 
and stored at -80 °C. 
3.3.2 RNA isolation 
Total RNA of the ipsilateral and contralateral sides of the spinal cord was extracted using 
Trizol reagent. All steps were performed at room temperature, exceptions are mentioned 
below. 
For isolation, 0.3-0.5 ml Trizol reagent was added to 30-50 mg spinal cord tissue and 
homogenized using a pistil. After centrifugation at 12000 g for 10 min at 4 °C to remove 
insoluble material, the supernatant was transferred to a fresh 1.5 ml Eppendorf tube. 1-
Bromo-3-chloropropane (30-50 μl) was added to the samples and mixed. For phase 
separation, samples were incubated for 3 min and centrifuged at 12000 g for 10 min at 4 °C. 
The aqueous phase was transferred to a fresh 1.5 ml tube. 
To precipitate RNA, 250 μl isopropanol was added and samples were incubated for 
10 min. After 10 min centrifugation at 12000 g at 4 °C the supernatant was discarded and the 
RNA pellet washed with 1 ml 75 % ethanol. After repeated centrifugation the supernatant 
was discarded and the RNA pellet was air-dried for ≈ 30 min. The RNA was then redissovled 
in 20 μl DEPC water and incubated for 10 min and additional 15 min at 55 °C. For some 
samples, where the A260/A280 ratio was very low or high (see 3.3.3), an additional cleaning 
step was performed. Therefore, the samples were reprecipitated with 250 μl isopropanol and 
repeatedly treated following the protocol above. 
3.3.3 Determination of RNA concentration 
RNA concentrations can be determined by measuring the sample absorbance at 260 nm 
(A260) using a spectrophotometer (NanoDrop, ND 1000). An absorbance of 1 unit at 260 nm 
thereby corresponds to 40 μg of RNA per milliliter. The ratio of the sample absorbance at 260 
nm and 280 nm (A260/A280) provides similarly an estimate of the purity of RNA regarding 
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contaminants such as protein. Pure RNA has an A260/A280 ratio of 1.8 to 2.0. After 
determination of RNA concentration, samples were stored at -80 °C. 
3.3.4 Reverse transcription 
mRNA was transcribed into double-stranded cDNA using Reverse Transcriptase II and 
Oligo(dt)12-18 primer (Life Technologies). In each reaction sample a total of 1 μg RNA was 
used for transcription. The PCR machine was set up as follows: 
 
Temperature         Duration 
70 °C           10 min 
 4 °C          < 3 min  
First strand buffer, dNTPs and DTT were added 
42 °C             2 min 
4 °C          < 3 min  
Reverse Transcriptase II was added 
42 °C           60 min 
70 °C           15 min  
 4 °C         < 10 min  
 
After the reverse transcription all samples were filled up to 40 μl with RNAse free water to 
reach a final cDNA concentration of 25 ng/μl and were stored at –20 °C. 
 
3.3.5 Quantitative real time-PCR 
For the gene expression analysis TaqMan® gene expression assays were used. TaqMan 
assays base on a gene specific probe coupled to a fluorophore and a quencher. After binding 
to the specific cDNA sequence during amplification the fluorophore is separated from the 
quencher and emits a fluorescence signal. The number of amplification cycles needed to 
detect a sufficient fluorescence signal gives information about the relative amount of specific 
cDNA in the sample.  
For each sample 50 ng of cDNA were mixed with gene expression master mix (containing 
AmpliTaq Gold® DNA Polymerase, Life Technologies) and with one of the gene specific 
assays (CB2, Nos2, igtp, tgtp, IL-1β or Actb; see 2.7; Life Technologies), centrifuged and 
stored in the dark on ice until the start of the measurement. The thermal cycling in the 
Taqman 7900HT was proceeded as the follows: 
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Step     Temperature  Duration Number of cycles 
Initial denaturation   95 °C   10 min  1 cycle 
Denaturation    95 °C   15 s 
Annealing/extension   60 °C   1 min   40 cycles 
 
Data displayed by the SDS analyzing software (Applied Biosystems; SDS 2.2.2) were 
normalized to a housekeeping gene (β-actin) and analyzed with the 2-ΔΔCt method as 
described previously (Livak and Schmittgen, 2001). β-actin (Actb) was chosen as 
housekeeping gene because it was shown to be stably expressed during neuropathic pain 
conditions (Wan et al., 2010). 
3.3.6 Statistical analysis of biomolecular data 
For biomolecular analyses a factorial ANOVA was applied. Categorical factors were 
surgery, side and treatment. For the CB2 expression analysis, we used the Fisher-LSD post-
hoc test for the interaction of surgery and side followed the analysis. The level of significance 
was set at p ≤ 0.05.  
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4 RESULTS 
The present data were divided into two main parts to investigate the role of CB2 receptors 
in the modulation of chronic neuropathic pain. In the first part, the therapeutic potential of the 
natural CB2 receptor agonist BCP was evaluated in the treatment of neuropathic pain. Here, 
we used the partial sciatic nerve ligation as a model for neuropathic pain. 
In the second part, the role of CB2 receptors for the development of chemotherapy-
induced neuropathic pain was evaluated. Here, a mouse model of paclitaxel-induced 
neuropathic pain was established and genotype effects between wild type and CB2 knockout 
mice were studied. 
4.1 The natural CB2 receptor agonist BCP in the 
treatment of neuropathic pain 
4.1.1  Neuropathic pain symptoms were diminished in BCP treated 
wild type mice 
Painful responses towards normally innocuous mechanical stimuli (allodynia) and 
decreased thresholds towards noxious thermal stimuli (hyperalgesia) are indicators for the 
development of neuropathic pain (Costigan et al., 2009). Therefore, mice were tested in the 
von Frey test for mechanical allodynia and in the Hargreaves’ test for thermal hyperalgesia.  
Baseline responses of male mice in the von Frey test were similar between the different 
treatment groups. As baseline responses in the Hargreaves’ test differed between some 
groups, data were here expressed as percent of baseline.  
The partial ligation of the right sciatic nerve induced mechanical allodynia and thermal 
hyperalgesia in ipsilateral hind paws, revealed by significantly decreased mechanical 
withdrawal thresholds compared to contralateral hind paws in the von Frey test (Figure 8 A; 
side; F1,18 = 387.34, p < 0.001) and thermal withdrawal latencies in the Hargreaves’ test 
(Figure 8 B; F1,18 = 20.40, p < 0.001). The mechanical (F1,22 = 0.44, p > 0.05) or thermal 
withdrawal responses (F1,22 = 0.58, p > 0.05) in sham-operated mice remained unaffected 
(Figure 9 A and B). 
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Figure 8 Effect of different doses (0.1, 1, 5 and 10 mg/kg) of BCP and JWH-133 (1 and 
5 mg/kg) treatment on mechanical allodynia and thermal hyperalgesia in PNL wild type mice.  
A 1, 5 and 10 mg/kg BCP and 1 and 5 mg/kg JWH-133 treatment significantly reduced PNL-induced 
mechanical allodynia in the ipsilateral side. B Only 1 mg/kg BCP treatment significantly reduced PNL-
induced thermal hyperalgesia in the ipsilateral side, while treatment with 1 and 5 mg/kg JWH-133 
showed no effect. Ipsilateral and contralateral hind paws of male mice were tested in the von Frey test 
and Hargreaves’ test to evaluate mechanical allodynia and thermal hyperalgesia. Mice were tested at 
day 3, 6, 8, 10 and 14 after surgery (vehicle: n= 10; 0.1 mg/kg BCP: n = 8; 1 mg/kg BCP: n = 10; 
5 mg/kg BCP: n = 11; 10 mg/kg BCP: n = 10; 1mg/kg JWH-133: n = 8; 5 mg/kg JWH-133: n = 10). 
Thermal withdrawal latencies are expressed as percent of basal responses. B = basal responses. **, 
treatment p < 0.01, ***, treatment p < 0.001. Means + SEM are indicated. 
 
 
RESULTS 35 
 
 
 
 
Figure 9 Effect of different doses (0.1, 1, 5 and 10 mg/kg) of BCP and 1 and 5 mg/kg JWH-
133 treatment on mechanical allodynia and thermal hyperalgesia in sham-operated wild type 
mice. A Mechanical withdrawal thresholds of sham operated mice were not affected by BCP or JWH-
133 treatment. B Also thermal withdrawal latencies of sham-operated mice were not altered by the 
BCP or JWH-133 treatment. Ipsilateral and contralateral hind paws of male mice were tested in the 
von Frey test and Hargreaves’ test to evaluate mechanical allodynia and thermal hyperalgesia. Mice 
were tested at day 3, 6, 8, 10 and 14 after surgery (vehicle: n= 12; 0.1 mg/kg BCP: n = 5; 1 mg/kg 
BCP: n = 6; 5 mg/kg BCP: n = 6; 10 mg/kg BCP: n = 3; 1 mg/kg JWH-133: n = 6). Thermal withdrawal 
latencies are expressed as percent of basal responses. It has to be considered that replicate number 
of sham animals was low in some groups as they accompanied experiments as controls but were not 
part of the main investigation. B = basal responses. Means + SEM are indicated. 
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BCP treatment in male mice 
To evaluate the effect of orally administered BCP on the development of neuropathic pain, 
mice received daily BCP-treatment (0.1, 1, 5 or 10 mg/kg dissolved in olive oil) by gavage. 
The doses of 1 and 5 mg/kg BCP increased mechanical withdrawal thresholds of 
ipsilateral hind paws gradually over the testing period of two weeks, starting from 3.31 g at 
day 3 to 4.04 g at day 14 (1 mg/kg) and from 3.29 g at day 3 to 3.79 g at day 14 (5 mg/kg), 
respectively (Figure 8 A). Treatment with 10 mg/kg exhibited directly a robust effect on day 3 
(3.81 g), which then slightly decreased over the testing period to 3.26 g. When comparing 
these results to the vehicle treated groups, a significant treatment effect for all three doses 
was revealed (1 mg/kg: F1,18 = 20.66, p > 0.001; 5 mg/kg: F1,19 = 20.47, p < 0.0001; 10 mg/kg: 
F1,18 = 33, p < 0.001), while the treatment with 0.1 mg/kg BCP produced no significant effect 
(0.1 mg/kg: F1,16 = 2.57, p > 0.05). 
Only treatment with 1 mg/kg BCP also decreased thermal hyperalgesia in the Hargreaves’ 
test. This dose even rescued the thermal withdrawal latencies to basal levels after two 
weeks, from 74.69 % of basal at day 3 to 108.69 % of basal at day 14 (Figure 8 B). Statistical 
analysis again revealed a significant treatment effect for this dose (F1,18 = 9.12, p = 0.007) and 
a significant time and treatment interaction (F4,72 = 2.93, p = 0.026). The doses of 0.1, 5 and 
10 mg/kg BCP did not affect thermal withdrawal latencies (0.1 mg/kg: F1,16 = 0.00, p > 0.05; 
5 mg/kg: F1,19 = 0.24, p > 0.05; 10 mg/kg: F1,18 = 0.29, p > 0.05). The dose of 1 mg/kg BCP 
thus seemed to be the most effective.  
BCP treatment did not influence mechanical (0.1 mg/kg BCP: F1,15 = 0,04, p > 0.05; 
1 mg/kg BCP: F1,16 = 1.09, p > 0.05; 5 mg/kg BCP: F1,16 = 0.01, p > 0.05; 10 mg/kg BCP: F1,13 = 
0.03, p > 0.05) or thermal withdrawal responses (0.1 mg/kg BCP: F1,16 = 2.95, p > 0.05; 
1 mg/kg BCP: F1,16 = 0.34, p > 0.05; 5 mg/kg BCP: F1,16 = 0.08, p > 0.05; 10 mg/kg BCP: F1,13 = 
4.18, p > 0.05) of ipsilateral hind paws in sham-operated mice (Figure 9, A and B).  
BCP treatment in female mice 
To evaluate if BCP treatment similarly induces anti-nociceptive effects in female mice, 
experiments were repeated in female wild-type mice. The partial ligation of the right sciatic 
nerve induced mechanical allodynia (Figure 10, A; side; F1,18 = 173.66, p < 0.001) and thermal 
hyperalgesia (Figure 10, B; F1,18 = 10.99, p < 0.003) in the ipsilateral hind paw of female mice. 
The sham operation had no effect on mechanical (F1,4 = 0.59, p > 0.05) or thermal withdrawal 
responses (F1,4 = 0.13, p > 0.05). Here, it has to be considered that replicate number for 
female sham animals was low as they accompanied experiments as controls but were not 
part of the main investigation. 
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Figure 10 BCP treatment attenuated PNL-induced mechanical allodynia and thermal 
hyperalgesia in female wild type mice. A Treatment with 1 mg/kg BCP significantly attenuated 
mechanical allodynia in ipsilateral hind paws of female mice. B Treatment with 1 mg/kg BCP showed 
no significant reduction of thermal hyperalgesia in female mice, although their mean withdrawal 
latencies were higher compared to vehicle animals. C Mechanical withdrawal thresholds of sham 
operated mice. D Thermal withdrawal latencies of sham-operated mice. Ipsilateral and contralateral 
hind paws of female mice were tested in the von Frey test and Hargreaves’ test to evaluate 
mechanical allodynia and thermal hyperalgesia. Mice were tested at day 3, 6, 8, 10 and 14 after 
surgery (PNL + vehicle: n = 10; PNL + 1mg/kg BCP: n = 5, Sham + vehicle: n = 3; Sham + 1mg/kg 
BCP: n = 3). Thermal withdrawal latencies are expressed as percent of basal responses. B = basal 
responses. **, treatment p < 0.01. Means + SEM are indicated. 
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The dose of 1 mg/kg of BCP was chosen for the treatment of female wild type mice. Similar 
to male mice, chronic treatment with 1 mg/kg BCP significantly decreased mechanical 
allodynia (Figure 10, A; treatment: F1,13 = 10.49, p = 0.006) in ipsilateral sides. The treatment 
effect for thermal hyperalgesia was not significant (Figure 10, B; F1,13 = 3.30, p = 0.093). BCP 
treatment did not influence mechanical (F1,4 = 0.14, p > 0.05) or thermal withdrawal thresholds 
(F1,4 = 1.92, p > 0.05) of sham-operated mice (Figure 10, C + D). 
Treatment with the synthetic CB2 agonist JWH-133  
As a reference, daily subcutaneous injections of the synthetic CB2 receptor agonist JWH-
133 in the doses of 1 and 5 mg/kg were used. This treatment significantly increased the 
mechanical withdrawal thresholds at both doses compared to vehicle-treated mice (Figure 8; 
treatment: 1 mg/kg: F1,16 = 9.59, p = 0.0069; 5 mg/kg: F1,18 < 0.001), but failed to diminish 
thermal hyperalgesia in the Hargreaves’ test (Figure 9; 1 mg/kg: F1,16 = 0.54, p > 0.05; 
5 mg/kg: F1,18 = 1.53, p > 0.05). 
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4.1.2 BCP treatment inhibited neuropathic pain through CB2 
receptor activation 
To determine if BCP exerts its analgesic effects in neuropathic pain via CB2 receptor 
activation, the experiments were repeated in CB2 knock-out mice.  
As it was shown previously (Rácz et al., 2008b), baseline responses of CB2 knock-out 
mice were similar to wild type mice. After the partial nerve ligation vehicle treated CB2 knock-
out mice developed mechanical allodynia and thermal hyperalgesia in the ipsilateral side. 
This was revealed by significantly decreased mechanical withdrawal thresholds in the von 
Frey test (Figure 11, A; surgery; F1,14 = 25.97, p < 0.001) and thermal withdrawal latencies in 
the Hargreaves’ test (Figure 11, B; F1,19 = 4.97, p = 0.038). In the contralateral side CB2 
knock-out mice additionally developed a mirror image of mechanical hyperalgesia (F1,14 = 
8.39, p = 0.012) as reported previously (Rácz et al., 2008b), but no thermal hyperalgesia 
(F1,19 = 0.34, p > 0.05). The sham operation did not influence the pain responses to 
mechanical (side; F1,14 = 0.13, p > 0.05) and thermal stimuli (F1,20 = 2.27, p > 0.05).  
Previously, we identified that the dose of 1 mg/kg BCP was the most effective dose in the 
neuropathic pain model in wild type mice. Therefore, this dose was chosen for the treatment 
of the CB2 knock-out mice. Here, 1 mg/kg BCP failed to show any effects on mechanical 
allodynia in the ipsilateral side (Figure 11, A; treatment: F1,15 = 0.83, p > 0.05) or contralateral 
side (F1,15 = 1.19, p > 0.05). Similarly, thermal hyperalgesia in ipsilateral hind paws was also 
not affected by BCP treatment (Figure 11, B; F1,20 = 0.08, p > 0.05). BCP treatment similarly 
did not influence the responses of ipsilateral hind paws in sham-operated CB2 knock-out 
mice (Figure 11, C + D; von Frey: F1,17 = 0.01, p > 0.05; Hargreaves’: F1,23 = 0.72, p > 0.05). 
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Figure 11 BCP treatment did not attenuate PNL-induced mechanical allodynia and thermal 
hyperalgesia in CB2 knock-out mice. A Treatment with 1 mg/kg BCP did not alter mechanical 
allodynia in ipsilateral hind paws of CB2 knock-out mice (vehicle: n = 8; 1mg/kg BCP: n = 9). 
Additionally to the ipsilateral side, CB2 knock-out mice developed a mirror image of pain at the 
contralateral side after surgery (Rácz et al., 2008) B Treatment with 1 mg/kg BCP also had no 
influence on thermal hyperalgesia in CB2 knock-out mice (vehicle: n = 10; 1mg/kg BCP: n = 12). 
C Mechanical withdrawal thresholds of sham operated mice (vehicle: n = 8; 1mg/kg BCP: n = 11). 
D Thermal withdrawal latencies of sham operated mice (vehicle: n = 11; 1mg/kg BCP: n = 14). 
Ipsilateral and contralateral hind paws of CB2 knock-out mice were tested in the von Frey test and 
Hargreaves’ test to evaluate mechanical allodynia and thermal hyperalgesia. Mice were tested at day 
3, 6, 8, 10 and 14 after surgery. Thermal withdrawal latencies are expressed as percent of basal 
responses. B = basal responses. Means + SEM are indicated.  
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4.1.3 BCP elicited no psychomimetic effects in the tetrad test 
In earlier studies (Gertsch et al., 2008) and in the present study, it was shown that BCP 
exerts its anti-nociceptive effects through specific CB2 receptor activation. To determine if 
BCP treatment is devoid of CB1 mediated psychomimetic side effects, wild type mice were 
tested in the tetrad test. CB1 receptor activation leads to distinct behavioral changes, like 
hypomotility, hypothermia, catalepsy and analgesia (Martin et al., 1991). The tetrad test, 
therefore, includes the open field test, catalepsy on a ring, tail flick test and the measurement 
of body temperature. The doses of 1 and 10 mg/kg BCP were used for acute treatment in the 
tetrad test as these doses represent the most effective (1 mg/kg) and the highest dose 
(10 mg/kg) used in the neuropathic pain model.  
 
 
 
Figure 12 Treatment with BCP did not elicit psychomimetic side effects in wild type mice. 
Mice were tested 45 min after an acute oral administration of 1 and 10 mg/kg BCP or vehicle (Veh; 
olive oil) in the tetrad test (vehicle: n = 7; 1 mg/kg BCP: n = 8; 10 mg/kg BCP: n = 8): Motor activity in 
the open field, immobility on a ring (catalepsy), anti-nociception in the tail flick test and hypothermia. 
Means + SEM are indicated 
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Body weights were similar between the groups. Mice treated with 1 and 10 mg/kg BCP were 
tested 45 min after the drug administration. Oral treatment with 1 and 10 mg/kg BCP did not 
induce CB1 mediated psychomimetic side effects (Figure 12). One-way ANOVA revealed 
that there were no significant activity changes in the open field (treatment: F2,20 = 0.59, p > 
0.05), no ring catalepsy (F2,20 = 1.14, p > 0.05) and no anti-nociception in the tail flick test 
(F2,20 = 0.33, p > 0.05). Similarly, no significant change in body temperature could be 
observed (Repeated measures ANOVA; treatment: F2,20 = 1.3, p > 0.05; time x treatment: 
F2,20 = 2.8, p > 0.05).  
Two groups of mice were treated with our positive-control compound Δ9-THC. One group 
was tested, similar to BCP-treated mice, 45 min after the treatment with Δ9-THC (5 mg/kg) 
and  one group was tested after  a  shorter period of  time and with a  higher dose of Δ9-THC 
 
Figure 13 Treatment with the reference compound Δ
9
-THC (10 mg/kg) produced typical CB1 
receptor-mediated behavioral changes in the tetrad test: Hypomotility, catalepsy, anti-
nociception and hypothermia. Wild type mice were tested 20 min after an acute intraperitoneal 
injection of Δ
9
-THC or vehicle (Veh; Cremophor) in the tetrad test (vehicle: n = 7; 10 mg/kg Δ
9
-THC: 
n = 6): Motor activity in the open field, immobility on a ring (catalepsy), antinociception in the tail flick 
test and hypothermia. ***, treatment p < 0.001. Means + SEM are indicated. 
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(20 min after treatment with 10 mg/kg) to archive a robust effect. Treatment with Δ9-THC 
elicited typical cannabinoid-induced behavioral changes. Mice treated with 10 mg/kg Δ9-THC 
were tested 20 min after the drug administration (Figure 13). They were less active in the 
open field (One-was ANOVA: F1,11 = 29.03, p < 0.001) and remained for a longer period 
immobile on the ring in the catalepsy test (F1,11 = 24.13, p < 0.001). Repeated measures 
ANOVA also revealed a significant drop in body temperature 35 min after the Δ9-THC 
treatment (treatment: F1,10 = 54.7, p > 0.001; time x treatment: F1,10 = 14.1, p > 0.004). Tail 
flick analgesia just failed to reach the level of significance (One-was ANOVA; F1,11 = 4.51, p = 
0.057). Mice treated with 5 mg/kg Δ9-THC were tested 45 min after drug administration 
(Figure 14). The dose of 5 mg/kg  Δ9-THC  also induced hypomotility (F1,11 = 6.80, p = 0.024),  
 
 
 
Figure 14 Treatment with the reference compound Δ
9
-THC (5 mg/kg) produced typical CB1 
receptor-mediated behavioral changes in the tetrad test: Hypomotility, catalepsy, anti-
nociception and hypothermia. Mice were tested 45 min after an acute intraperitoneal injection of Δ
9
-
THC or oral administration of vehicle (Veh; Olive oil) in the tetrad test (vehicle: n = 7; 5 mg/kg Δ
9
-THC 
n = 6): Motor activity in the open field, immobility on a ring (catalepsy), antinociception in the tail flick 
test and hypothermia. *, treatment p < 0.05; **, treatment p < 0.01; ***, treatment p < 0.001. Means + 
SEM are indicated.  
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catalepsy (F1,11 = 50.59, p < 0.001) and hypothermia (Repeated measures ANOVA; time x 
treatment; F1,11 = 14.19, p = 0.0037). Solely in the tail flick test no significant analgesic effects 
could be observed (F1,11 = 1.04, p = 0.328). 
 
 
4.1.4 BCP reduced the density of glia cell immunoreactivity in the 
lumbar spinal cord 
Development of neuropathic pain is accompanied by the activation and proliferation of glia 
cells in the spinal cord (Scholz and Wolf, 2007). Therefore, we performed histological 
stainings using the astrocyte marker glial fibrillary acidic protein (GFAP) and microglia 
marker ionized calcium-binding adapter molecule 1 (Iba1). 
In the first staining series using cryosections of non-perfused tissue, the density of 
astrocytes signals in the ipsilateral dorsal horns of lumbar spinal cord was significantly 
increased in vehicle treated PNL mice compared to sham-operated mice (Figure 15, A, B; 
Mann-Whitney U-test; U = 56; p = 0.019). Treatment with BCP strongly reduced astrocyte 
signals in the dorsal horn of PNL mice in comparison to the vehicle control mice (U = 58; p = 
0.023) and normalized astrocyte levels to that of sham-operated mice (U = 59; p > 0.05).  
As the microglia staining in the first staining series was too faint for quantification, a 
second staining series was performed using cryosections of perfused tissue. 
The results of the second GFAP staining were in accordance with the findings of the first 
series. The partial nerve ligation induced an increase in astrocyte signals in the ipsilateral 
dorsal horns compared to sham operation (Figure 17; U = 164; p = 0.003). Treatment with 
BCP reduced the mean percentage of stained area in PNL mice, but this effect failed to 
reach significance (U = 226, p > 0.05). Nevertheless, the density of astrocyte signals in the 
BCP treated PNL group was not significantly different from that of sham-operated BCP mice 
(U = 188, p > 0.05). 
Similarly, the partial nerve ligation strongly increased microglia signals in the ipsilateral 
dorsal horns of lumbar spinal cord sections (Figure 16). Quantitative analysis revealed that 
this effect was highly significant, when compared to sham operated vehicle-treated mice (U = 
25, p < 0.001). After treatment with BCP, a robust decrease in the density of microglia 
signals in dorsal horns compared to vehicle control mice was observed (U = 164, p = 0.006). 
However, the density of microglia in PNL mice was still significantly higher than in sham 
animals (U = 23, p < 0.001). 
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Figure 15  Chronic treatment with 1 mg/kg BCP reduced the mean density of astrocyte 
signals in the ipsilateral dorsal horn of the lumbar spinal cord. A Representative pictures of the 
glial fibrillary acidic protein (GFAP) immunostaining in the contralateral and ipsilateral dorsal horns of 
the lumbal spinal cord recorded with the 20x (red frame) and 40x (black frame) magnification 
objective. B Quantitative analyses revealed a reduction of astrocyte signals in the ipsilateral dorsal 
horn in 1 mg/kg BCP treated mice (n = 3 per group). C Schematic picture of a transverse lumbar 
spinal cord section. *, treatment p < 0.05;  #, surgery p < 0.05. Means + SEM are indicated. 
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Figure 16 Chronic treatment with 1 mg/kg BCP reduced the mean density of microglia 
signals in the ipsilateral dorsal horn of the lumbar spinal cord. A Representative pictures of the 
Iba1 immunostaining in whole lumbar spinal cord sections recorded with the 20x magnification 
objective. Ipsilateral dorsal horns are located on the right, contralateral dorsal horns accordingly on the 
left. B Magnification of Iba1 stained ipsilateral dorsal horns recorded with the 20x magnification 
objective (see white frame in A). C Quantitative analyses (see also Figure 7) revealed a reduction of 
microglia signals in the ipsilateral dorsal horn (normalized to contralateral dorsal horn) after two weeks 
of 1 mg/kg
-
 BCP treatment (n = 4-5 per group). **, treatment p < 0.01;  ***, surgery p < 0.001. Means + 
SEM are indicated. 
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Figure 17 Chronic treatment with 
1 mg/kg BCP reduced the mean density 
of astrocytes signals in the ipsilateral 
dorsal horn of the lumbar spinal cord. A 
Representative pictures of the GFAP 
immunostaining in the ipsilateral dorsal 
horns of lumbar spinal cord sections 
recorded with the 20x magnification 
objective. B Although quantitative analyses 
(see also Figure 7) revealed that the 
treatment in PNL mice did not significantly 
decrease astrocytes signals after two weeks 
of 1 mg/kg
-
 BCP treatment compared to 
vehicle mice, mean values here were similar 
to that of sham operated mice (n = 4-5 per 
group). ***, surgery p < 0.001. Means + 
SEM are indicated. 
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4.1.5 Biomolecular analysis 
To further study possible molecular downstream targets of the BCP treatment, quantitative 
real-time PCR was performed and the expression patterns of the CB2 receptor, inducible 
nitric oxide synthase 2 (iNOS), interferon-γ induced GTPase (igtp), T-cell specific GTPase 1 
(tgtp) and interleukin-1β (IL-1β) mRNA was analyzed. 
The partial ligation of the sciatic nerve induced an increase in CB2 receptor mRNA in the 
ipsilateral side, but not in the contralateral side, as revealed by a significant interaction of 
surgery and side in the factorial ANOVA (F1,29 = 4.63, p = 0.03). The following Fisher-LSD 
post-hoc test revealed that ipsilateral PNL values were significantly increased compared to 
ipsilateral sham values (Figure 18; p = 0.0096). The CB2 receptor expression was not 
influenced by the BCP treatment (treatment: F1,29.= 1.51; p > 0.05).  
iNOS expression was not significantly modulated, although mean iNOS expression was 
increased in the ipsilateral sides, the main effect failed to reach the level of significance (side: 
F1,29 = 4.00, p = 0.0550).  
We found no modulation in the expression patterns of Igtp, Tgtp and Il-1β, neither by the 
surgery nor by the BCP treatment.  
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Figure 18 Quantitative analysis of mRNA levels of CB2, iNOS, Igtp, Tgtp, IL-1β in the 
lumbar dorsal horn of partial nerve ligated mice compared to sham operated mice (n = 4-5 per 
group). The partial nerve ligation induced an up-regulation of CB2 mRNA in the ipsilateral side of 
lumbar dorsal horn in vehicle and BCP-treated mice compared to vehicle treated sham mice. Neither 
the partial nerve ligation nor the BCP treatment changed the mRNA levels of iNOS, Igtp, Tgtp or IL-1β. 
**, Fisher-LSD post-hoc test for surgery x side, p < 0.05. Means + SEM are indicated. 
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4.2 Paclitaxel-induced neuropathic pain in CB2
 
knock-out and wild type mice 
A further mouse model of neuropathic pain was established to investigate the role of the 
CB2 receptor during chronic pain development. Chemotherapeutic drug-induced neuropathic 
pain is initiated by different mechanisms from those in traumatic nerve injury models and yet 
not studied well. Therefore, the chemotherapeutic agent paclitaxel was administered in wild 
type and CB2 knock-out mice.  
The treatment with paclitaxel only minimally influenced the overall health state of mice. 
Both, CB2 knock-out and wild type mice gained normal weight during the experiments and 
repeated measures ANOVA revealed no significant differences in weight between the strains 
(Figure 20, strain; F1,14 = 0.21; p > 0.05).  
 
  
Figure 19 Development of mechanical allodynia, but not thermal hyperalgesia in CB2 
knock-out and wild type mice during and after the treatment with Paclitaxel. To induce ne 
uropathic pain four injections of 4 mg/kg Paclitaxel were administered on alternative successive days 
(day 0, 2, 4 and 6; arrows). Ipsilateral and contralateral hind paws of CB2 knock-out (CB2ko) and wild 
type mice (WT) were tested in the von Frey test (A) and Hargreaves’ test (B) to evaluate mechanical 
allodynia and thermal hyperalgesia (CB2 knock-out: n = 12; wild type: n = 10). Wild type and CB2 
knock-out mice were tested at day 4, 7, 11, 15, 22 and 30 after the first injection. Data are expressed 
as percent of basal responses. Fisher-LSD post-hoc test for time x strain: ***, CB2ko compared to 
basal p < 0.001; **, CB2ko compared to basal p < 0.01; *, CB2ko compared to basal p < 0.05; 
#
, WT 
compared to basal p < 0.05. Means + SEM are indicated. B = basal responses.  
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4.2.1 CB2 knock-out mice were more susceptible to paclitaxel 
treatment than wild type mice 
In a first testing series mechanical allodynia and thermal hyperalgesia were measured in 
paclitaxel-treated CB2 knock-out and wild type mice. Interestingly, wild type mice developed 
less signs of mechanical allodynia than CB2 knock-out mice. Thus, a significant strain effect 
and time x strain interaction in the von Frey test was observed (Figure 19, A; repeated 
measures ANOVA, strain: F1, 42 = 10.62, p = 0.002; time x strain: F6, 252 = 4.05, p < 0.001). A 
following Fisher-LSD post-hoc test for time and strain revealed significantly decreased 
mechanical withdrawal thresholds in CB2 knock-out mice at all test days (day 4: p = 0.0105; 
day 7: p = 0.0018; day 11, 15, 22 and 30: p < 0.001) in comparison to base values, while 
mechanical withdrawal thresholds in wild type mice were solely decreased at day 4 (p = 
0.0200), 22 (p = 0.0186 ) and 30 (p = 0.0151). In the Hargreaves’ test neither CB2 knock-out 
mice nor wild type mice showed signs of thermal hyperalgesia (Figure 19, B; strain: F1, 42 = 
0.43, p > 0.05; time x strain: F6, 252 = 0.51, p > 0.05).  
 
4.2.2 Paclitaxel induced no signs of cold allodynia 
In a second testing series the measurement of cold allodynia was performed additionally 
to mechanical allodynia. Because there was no effect observed in the Hargreaves’ test in the 
first testing series, which is also in line with the literature (Smith et al., 2004), we did not 
determine the thermal hyperalgesia here.  
Although repeated measures ANOVA showed no significant effect for the factor strain in 
the von Frey test this time (Figure 20, B; F1, 32 = 1.22, p > 0.05), the factors time and strain 
showed a significant interaction (F6, 192= 2.27, p = 0.038). Fisher LSD post hoc analysis 
revealed decreased mechanical withdrawal thresholds of CB2 knock-out mice on day 22 and 
30 compared to basal level (p = 0.002, p = 0.014), but not in wild type mice (p > 0.05). In 
contrast to former reports (Smith et al., 2004), neither CB2 knock-out mice nor CB2 wild type 
mice developed cold allodynia during the testing period of four weeks (Figure 20, C; strain: 
F1, 32 = 0.01, p > 0.05; time x strain: F6, 192 = 0.31, p > 0.05). 
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Figure 20 No alterations in body weight 
or cold allodynia were observed in both 
strains during and after the treatment with 
paclitaxel. Paclitaxel significantly reduced 
mechanical withdrawal thresholds on day 22 and 
30 compared to basal values in CB2 knock-out 
mice (CB2ko), but not in wild type mice (WT). 
The body weight was assessed and ipsilateral 
and contralateral hind paws of CB2 knock-out 
and wild type mice were tested in the von Frey 
test (B) and Cold plate test (C) to evaluate 
mechanical allodynia and cold allodynia (CB2 
knock-out: n = 10; wild type: n = 7). Wild type 
and CB2 knock-out mice were tested at day 4, 7, 
11, 15, 22 and 30 after the first injection. Data 
are expressed as percent of basal responses. 
Fisher-LSD post-hoc test for time x strain: *, 
CB2ko compared to basal p < 0.05; **, CB2ko 
compared to basal p < 0.01. Means + SEM are 
indicated. B = basal responses.  
-
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5 DISCUSSION 
Chronic neuropathic pain is a debilitating condition with strong impacts on patients’ mood 
and daily life routine. Although a lot of effort has been put in the establishment of new and 
effective therapies, treatment of neuropathic pain is still a challenging issue as the whole 
pain processing is altered. The endocannabinoid system seems to be a promising target for 
the development of new pain therapies as the analgesic effects of the cannabinoid 
constituents in the essential oil of Cannabis sativa are known since thousands of years (Zias 
et al., 1993). However, psychoactive side effects due to central receptor activation constrain 
their therapeutic use and authorization (Ben Amar, 2006). It is now well-documented that the 
peripheral CB2 receptor plays an important role in the development of neuropathic pain and 
that its activation alone is sufficient to reduce chronic pain associated with nerve injury 
(Beltramo, 2009; Guindon and Hohmann, 2008).  
The present study investigated the properties of the phytocannabinoid BCP, a selective 
CB2 receptor agonist, to ameliorate mechanical allodynia and thermal hyperalgesia in mice 
with a partial nerve ligation, measured in two behavioral tests (von Frey and Hargreaves’ 
test). The pharmacological specificity of the anti-nociceptive effects to CB2 receptor 
activation was verified by the use of CB2 receptor knockout mice. Acute BCP treatment 
induced no possible psychomimetic side effects, which are associated with CB1 receptor 
activation, in the tetrad test. Furthermore, histological analyses revealed a decrease in the 
inflammatory response (microglia and astrocyte activation) in the dorsal horn of the lumbar 
spinal cord after BCP treatment, which is a hallmark after nerve injury and accompanying the 
occurrence of pain.  
In the last part of the study a second mouse model for neuropathic pain was established. 
Mice were treated with the chemotherapeutic agent paclitaxel to induce neuropathic pain 
symptoms, which were evaluated in three behavioral tests (von Frey, Hargreaves’ and Cold 
plate test). A comparison between CB2 knockout mice and wild type littermates revealed that 
the CB2 receptor knock-out mice were more susceptible to paclitaxel treatment than wild 
type mice.  
Both experimental approaches emphasize the involvement of CB2 receptors in the 
development of neuropathic pain and are further discussed in the following sections.  
DISCUSSION 54 
 
5.1 Anti-nociceptive effects of the plant volatile BCP 
The plant sesquiterpene and food additive BCP was recently found to be a highly 
selective, natural CB2 receptor agonist ((E)-BCP: Ki = 155 ± 4 nM) with a structure totally 
unrelated to classical phytocannabinoids (Gertsch, 2008; Gertsch et al., 2008; Gertsch et al., 
2010). In vitro studies with CHO-K1 cells expressing human CB2 receptors verified that BCP 
activates the whole Gi/o protein signaling machinery known from CB2 receptor activation: it 
inhibited cAMP production, initiated intracellular Ca2+ release and phosphorylation of MAPK-
ERK1/2 and p38. The same authors similarly provided evidence for beneficial effects of BCP 
in vivo by using an animal model of inflammatory pain (carrageenan model). Interestingly, 
BCP showed a stronger anti-inflammatory effect in this model as the synthetic CB2 receptor 
JWH-133, although the binding affinity of JWH-133 to CB2 receptors is higher (Ki = 3.4 nM) 
(Gertsch et al., 2008).  
As the source of chronic, inflammatory pain used in this former study is located in 
peripheral tissue, while the pathological processes of neuropathic pain underlie nerve injury 
(Devor, 2006), the present study focused on the effects of BCP in an animal model of 
peripheral nerve injury-induced neuropathic pain.  
Chronic treatment with BCP substantially ameliorated mechanical allodynia and thermal 
hyperalgesia in male and female mice after the partial ligation of the right sciatic nerve. 
These effects were likely attributed to selective CB2 receptor activation as they were 
completely absent in CB2 receptor knockout mice. Acute treatment with a low and a high 
dose of BCP completely lacked psychomimetic side effects, like hypomotiliy, anti-
nociception, hypothermia or catalepsy, seen in the tetrad test after cannabinoid intoxication. 
This suggests that BCP mediated no off-target effects at the tested doses by binding to 
central CB1 receptors, which could contribute to analgesia. The lack of psychomimetic side 
effects was also reported for several other synthetic CB2 agonists (Hanus et al., 1999; 
Kinsey et al., 2011; Rahn et al., 2011).  
No signs of tolerance were seen during the experimental time of two weeks. In contrary, 
the beneficial effects of BCP accumulated over time, which is clearly advantageous over 
other analgesic drugs like morphine that known to strongly induce tolerance after chronic 
administration. 
Interestingly, the pharmacological profile of BCP varied between the two tested 
modalities. The three higher doses of BCP (1, 5 and 10 mg/kg) diminished mechanical 
withdrawal responses in the von Frey test by a similar extend. Although the beneficial effects 
of BCP seemed to be more pronounced in 1 mg/kg and 5 mg/kg compared to 10 mg/kg, the 
lack of a clear dose-response in this modality might reflect the high potency of BCP to reach 
a maximal effect at low doses.  
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In contrast, thermal hyperalgesia was specifically reduced by the dose of 1 mg/kg BCP 
and therefore clearly showed an inverted U-shaped dose response curve for thermal 
withdrawal thresholds. 
These modality-specific differences of BCP treatment are probably underlying the different 
kind of nerve fibers involved in mechanical allodynia (Aβ-fibers) and thermal hyperalgesia (C-
fibers), and subsequent different mechanisms of initiation. While thermal hyperalgesia 
underlies a peripheral facilitation of small diameter C-fiber activity, which subsequently leads 
to a central sensitization, mechanical allodynia is mediated by large diameter Aβ-fibers. Due 
to central sensitization the input from mechanosensitive Aβ-fibers can also activate second-
order pain projection neurons in the spinal cord and stimuli like light touch can be perceived 
as painful (Baron, 2000). In line with this, studies of Curto-Reyes and colleagues (2010) 
suggested that only spinal CB2 receptors are involved in the anti-allodynic effects of CB2 
treatment in neuropathic pain, while both spinal and peripheral CB2 receptors mediate the 
antihyperalgesic effects. 
Although the therapeutic window of BCP in the treatment of mechanical allodynia was 
clearly broader, it cannot be excluded that higher doses of BCP would reveal the “missing” 
part of the inverted U-shaped dose-response curve for mechanical allodynia similarly to that 
seen in thermal hyperalgesia. 
A U-shaped dose-response effect for BCP treatment was already observed in the 
carrageenan model, where the lowest dose tested (5 mg/kg) showed the highest efficiency to 
reduce paw edema (Gertsch et al., 2008). Similarly, U-shaped dose response curves are 
repeatedly reported for cannabinoid agonists, e.g. for cannabidiol, AM124, WIN55212-2, 
BAY39-7271, HU-211 as well as for the endocannabinoid AEA (Sulcova et al., 1998; Malfait 
et al., 2000; Calabrese, 2008; Rahn et al., 2010). The underlying mechanisms are still not 
clarified, but could be subjected to a concentration-dependent, differential activation of G 
protein subsets (Gi and Go) leading to different or even opposing downstream effects. 
Shoemaker and colleagues could show in 2005 that the extend of intracellular signaling-
stimulation was not only agonist-specific but also concentration-dependent, e.g. 2-AG 
induced ERK-MAPK phosphorylation with low ED50 (half maximal effective dose), stimulated 
Ca2+ transients with a medium ED50 and inhibited adenylate cyclase with highest ED50 in 
Chinese hamster ovary cells. In contrast, noladin ether and CP-55,940 most potently 
inhibited adenylate cyclase followed with less potency by ERK-MAPK phosphorylation and 
Ca2+ transient-stimulation. Additionally to this concentration dependent activation of different 
signaling pathways, it cannot be excluded that off-target effects at high doses of BCP might 
oppose the CB2-mediated anti-nociceptive effects.  
The effects described above can also account for divergent results of the various CB2 
receptor-selective agonists on neuropathic pain symptoms or discrepancies between 
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research groups testing the same compound. So far, studies of CB2 receptor mediated anti-
nociceptive effects strictly used synthetic agonists with chemical structures often differing 
from the classical cannabinoids. Acute treatment with the aminoalkylindole AM1241dose-
dependently attenuated tactile and thermal hypersensitivity produced by spinal nerve ligation 
in rats (Ibrahim et al., 2003), while in naïve animals AM1241 produced anti-nociceptive 
effects in the Hargreaves’, but not the von Frey test, following here an inverted U-shaped 
dose-response curve similar to that found in the present study (Rahn et al., 2010). The 
synthetic CB2 selective, tricyclic pyrazole NESS400 was tested in a chronic treatment 
approach in a spared nerve injury model and exhibited modality-specific anti-nociception: it 
prevented the formation of thermal hyperalgesia at the highest dose tested, while mechanical 
allodynia was only transitorily reduced (Luongo et al., 2010). Although in the present study 
also a modality-specificity was found in the dose-response effects, the reduction of 
mechanical allodynia here remained over time. In 2008 Yamamoto and colleagues showed 
that a single intrathecal administration of JWH-133, a Δ8-THC derivative, which was similarly 
used as a reference compound in the present study, reversed partial sciatic nerve ligation-
induced mechanical allodynia. This effect was completely abolished in CB2 knockout 
animals. Single local or systemic administrations of JWH-133 in contrary were ineffective 
(Yamamoto et al., 2008). Although in the present study here a chronic treatment approach 
was used, these results are in line with the findings of Yamamoto et al. as JWH-133 similarly 
was able to reverse mechanical allodynia in the same animal model of pain. Nevertheless, 
under chronic treatment conditions the systemic administration (i.p.) of the drug was similarly 
efficient in a dose-dependent manner. Interestingly, no anti-hyperalgesic effects during the 
JWH-133 treatment were observed. As thermal withdrawal thresholds after JWH-133 
treatment were so far not tested in other studies, the present study shows for the first time 
that the JWH-133-mediated anti-nociceptive effects might be modality-specific. In 
comparison, the natural occurring BCP produced a more global anti-nociceptive effect than 
the synthetic JWH-133, although JWH-133 shows a greater binding affinity towards hCB2 
receptors as it was demonstrated before (Gertsch et al., 2008). 
Some points may have to be considered while comparing the results of CB2 receptor 
agonist on neuropathic pain: Most studies only tested smaller doses of the compounds, 
which could lead to the assumption of clear dose-response effects, although some 
compounds might exhibit an inverted U-shaped dose-response curve when testing a broader 
dose spectrum. Secondly, as there are no clear standards for testing pain killers in animals, 
pain studies comprise a variety of different animal models for neuropathic pain (e.g. spinal 
nerve ligation, chronic constriction model, partial nerve ligation, etc.), a variety of different 
behavioral tests for the same modality (e.g. von Frey hairs, dynamic von Frey devices, etc.) 
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to measure the pain outcome, and several routes of administration for the drugs, which 
makes it difficult to directly compare the compounds efficacy.  
Nevertheless, taken together all findings have clearly demonstrated that CB2 receptor 
activation alone is sufficient for attenuation of neuropathic pain symptoms and suggest an 
important role of peripheral and spinal CB2 receptors during neuropathic pain development. 
The natural source of BCP and the possibility of an oral intake as a dietary factor make BCP 
and interesting compound that could be clearly advantageous over other synthetic 
cannabinoid agonists in clinical practice. 
 
5.2 BCP reduced glia signals in the spinal cord  
Glia cells are thought to contribute to the development of neuropathic pain. Their 
activation and proliferation in the spinal cord parallels the development of neuropathic pain 
symptoms (Coyle, 1998). A fast activation and proliferation of microglia cells is seen as early 
as 4 hours after nerve injury in the dorsal horn of the lumbar spinal cord. This is followed by a 
late activation of astrocytes, which are gradually up regulated starting around postoperative 
day four (Tanga et al., 2004). These findings suggest that microglia are mainly involved in 
the initiation of neuropathic pain by the release of mediators that in turn activate astrocytes 
and further microglia cells. Astrocytes are thought to play a role in promoting and maintaining 
neuropathic pain, because it was shown that microglia activation decreases to baseline after 
three weeks, while astrocyte-activation and behavioral hypersensitivity remains (Tanga et al., 
2004; Hald et al. 2009). Both types of activated glia cells release several pro-inflammatory 
factors, e.g. IL-1β and TNF-α, that are known to induce neuropathic pain symptoms after 
central administration (Oka et al., 1995 and 1996), while an administration of their inhibitors 
is capable to attenuate neuropathic pain (Sommer et al., 1999; Schäfers et al., 2003). 
CB2 receptors are expressed on cells of immune origin and therefore also on microglia, 
the immune cells of the CNS (Facci et al., 1995; Howlett et al., 2004; Maresz et al., 2005). 
But CB2 receptors were also reported to be present in astrocytes under pathological 
conditions (Benito et al., 2007; Garcia-Ovejero, 2009). Due to their expression profile it is 
likely that CB2 receptors mediate their beneficial effects during neuropathic pain through a 
modulation of the inflammatory response. 
Insights into the role of CB2 receptor activation in glia cells during the development of 
neuropathic pain were given by experiments using CB2 receptor knockout mice. These mice 
exhibited not only an exaggerated glia response compared to wild type littermates, but the 
inflammation also spread to the contralateral dorsal horn, which was accompanied by 
mechanical allodynia and thermal hyperalgesia in the uninjured paw (Rácz et al., 2008b). In 
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contrary, activation of the CB2 receptor by intrathecal JWH-015 treatment was shown to 
decrease microglia and astrocyte activation in the lumbar spinal cord after paw incision 
(Romero-Sandoval et al., 2007). These results were confirmed by Luongo et al. using 
another CB2 agonist (NESS400), which similarly diminished the number of nerve injury-
induced activated microglia and astrocytes in the spinal projection area. It is hypothesized 
that CB2 receptor activation shifts microglia into an anti-inflammatory phenotype thereby 
reducing the expression of pro-inflammatory mediators like IL-1ß, IFN-γ and TNF-α, while 
increasing the expression of the anti-inflammatory IL-10 (Romero-Sandoval et al., 2009; 
Luongo et al., 2010). These results suggest that CB2 receptors are crucial key mediators in 
the control of the inflammatory response during pathological pain. 
The present histological analysis of Iba1 (microglia marker) and GFAP (astrocyte marker) 
staining in the lumbar dorsal horn of spinal cord slices similarly revealed increased signals of 
Iba1 and GFAP signals ipsilateral to the partial nerve ligation, but not to sham operation, in 
vehicle-treated mice. Treatment with the natural CB2 agonist BCP diminished Iba1 and 
GFAP expression in the dorsal horn, which is in line with the diminished hypersensitivity seen 
in the behavioral tests. The BCP treatment had no effect on Iba1 or GFAP expression in BCP 
treated sham animals compared to vehicle treated sham animals. This could be due to less 
activated glia cells in the absence of neuropathic pain and therefore less amounts of CB2 
receptors, which could be targeted by BCP.  
Together with the behavioral data the histological analyses suggest that BCP inhibits the 
formation of allodynia and hyperalgesia by immunomodulatory effects, rather than directly 
modulating the pain transmission in peripheral or central neurons. Consequently, BCP 
neither increased withdrawal thresholds towards noxious heat stimuli (Hargreaves test) in 
general (e.g. in sham animals) nor modulated acute pain responses in the tail flick test, 
features which are known from analgesic drugs like morphine (Whiteside et al., 2005; Rahn 
et al., 2010).  
5.3 CB2 receptors are up regulated in the spinal cord 
It is frequently reported that CB2 receptor expression is up regulated in DRGs and lumbar 
dorsal horns of the spinal cord after peripheral nerve injury, which correlates with the 
appearance of activated microglia (Zhang et al., 2003; Beltramo, 2006;Luongo et al., 2010). 
In the absence of CB2 receptors, gene expression profiles revealed an enhanced interferon-
γ response in lumbar spinal cords of mice suffering from neuropathic pain, which might 
account for the exaggerated, bilateral pain response reported for these mice (Rácz et al., 
2008a). Indeed, in interferon-γ/CB2 double knockout mice the exaggerated pain response 
after nerve injury was lost and pain development remained similar to that of wild type mice. 
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Interferon-γ is a cytokine that is involved in the host defense against pathogens and 
tumors and plays a comprehensive role in immunomodulation, e.g. in the regulation of 
cytokine production (IL-12, TNF-α) (Bach et al., 1997). Additionally, it induces the 
transcription of several guanosine triphosphatases (GTPases) (Mertens and Howard, 2006), 
some of which were also up regulated in the CB2 receptor knockout mice suffering from 
neuropathic pain. (Rácz et al., 2008a). The authors of this study postulated that interferon-γ, 
which is released by astrocytes and neurons, promotes the consolidation of neuropathic pain 
and induces several signaling pathways in microglia resulting in iNOS and chemokine 
receptor 2 up regulation. This in turn would lead to a further activation of microglia and 
astrocytes and interferon-γ release. Activation of the CB2 receptors could dampen this 
formation of a “vicious circle” and therefore anticipate an uncontrolled glial activation.  
To reveal if BCP mediates its effect by diminishing the interferon-γ response during 
neuropathic pain, expression analyses for the mRNAs of two interferon-γ-induced GTPases 
(igtp and tgtp), which were shown to be up regulated after nerve ligation (Rácz et al., 2008a), 
as well as analysis of CB2, iNOS and pro-inflammatory IL-1β mRNA were performed in the 
present study.  
As it was reported before for other neuropathic pain models (Luongo et al., 2010; Hsieh et 
al., 2011), CB2 receptor mRNA was up regulated in the ipsilateral, but not contralateral sides 
of mice with a partial sciatic nerve ligation. In sham animals no alterations in the CB2 mRNA 
expression were found compared to ligated animals nor did BCP treatment influence CB2 
mRNA expression. The CB2 receptor expression profile matched the sides of BCP-mediated 
anti-nociception: The withdrawal thresholds of ipsilateral sides were increased, but we found 
neither BCP-mediated alterations of the withdrawal thresholds of contralateral sides, nor that 
of sham animals. This is consistent with the general view that CB2 receptors only seem to 
play a minor role under normal, naïve conditions, but are markedly up regulated under 
various disease conditions at the sides involved in the disease (Pacher and Mechoulam, 
2011).  
In contrast to CB2 mRNA expression, no changes in the expression profile were found for 
iNOS, igtp, tgtp or IL-1β. The mean iNOS expression was increased in ipsilateral sides of 
mice with a partial nerve ligation, but this effect was not significant and clearly no treatment 
effect of BCP was seen in these animals. Although it was already shown that CB2 agonists 
are able to decrease pro-inflammatory IL-1β levels (Luongo et al., 2010), we found no 
treatment effect for IL-1β levels, but also no surgery effect. Eventually, here the wrong time 
point was chosen or an analysis of the actual protein level is a better approach for interleukin 
measurement and should be evaluated in future studies. 
The biomolecular results suggest that BCP diminishes not directly the interferon response, 
but is possibly acting through other signaling pathways, which might anticipate the 
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downstream interferon response. On the other hand it has to be considered that the mRNA 
analysis here only reveals a snapshot of the processes, which are going on during 
neuropathic pain. Again, a systematic analysis of different time points and analyses of the 
actual protein levels would certainly be required to give a clear answer to this issue. 
5.4 BCP: an all-round talent? 
Reviewing the recent literature, it becomes clear that the beneficial effects of BCP are not 
only restricted to neuropathic pain treatment. There are several health effects that have been 
attributed to BCP treatment. Our group already demonstrated that BCP exhibited anti-
inflammatory effects by inhibiting the formation of edema in the carrageenan model of 
inflammatory pain (Gertsch et al., 2008). Similarly, BCP reduced the pain responses in the 
late phase of the formalin test, a model of central sensitization, which was prevented in CB2 
knockout mice (Klauke et al., in preparation). Two recent studies reported that oral BCP 
treatment also inhibited colon inflammation and tissue damage in dextran sulfate sodium-
induced colitis, in which one study verified that CB2 and PPARγ receptor-activation, is 
required for these effects (Young et al., 2007; Bento et al., 2011). In a mouse model of 
cisplatin-induced nephrotoxicity, BCP ameliorated kidney dysfunction, renal inflammation and 
oxidative stress in a CB2 dependent manner (Horváth et al., 2012). Additionally, further 
beneficial effects of BCP have been reported that were not directly linked to CB2 receptor 
activation in these studies. These effects include local anaesthetic (Ghelardini et al., 2001), 
anti-carcinogenic (Di Sotto et al., 2010; Legault and Pichette, 2007; Loizzo et al., 2008), anti-
fibrotic (Calleja et al., 2012) and anxiolytic-like activity (Galdino et al., 2012). 
Besides the beneficial effects of BCP and other CB2 receptor agonists alone, cannabinoid 
agonist might also provide new opportunities for combination therapies. Cannabinoid and 
opioid receptors are co-expressed in areas, which are involved in pain processing, e.g. 
dorsal horn of the spinal cord (Welch and Stevens, 1992; Hohmann et al., 1999; Salio et al., 
2001), the periaqueductal grey, raphe nuclei and central medial thalamic nuclei (Mansour et 
al., 1988; Herkenham et al., 1991; Lichtman et al., 1996). It was shown that cannabinoid 
agonists increase the effectiveness of μ-opioid receptor agonists (Reche et al., 1996; 
Yesilyurt et al., 2003; Finn et al., 2004; Tham et al., 2005; Cox et al., 2007).  Additionally, 
evidence is raising that combination therapies with opioids and cannabinoids might reduce 
the development of morphine-induced tolerance. Morphine administration activates glia cells 
and the release of pro-inflammatory cytokines and chemokines, which counteracts the 
morphine-induced analgesia and enhances morphine tolerance and dependence (Watkins et 
al., 2009). CB2 receptor agonists were recently shown to down regulate the morphine-
induced activation of glia and thereby might increase the effectiveness of opioids in long-term 
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use (Tumati et al., 2012; Merighi et al., 2012). Similarly, there are reports showing that CB2 
receptor agonists are increasing the analgesic effects of non-steroidal anti-inflammatory 
drugs (NSAIDs) (Guindon et al., 2006a,b; Ulugöl et al., 2006). Finally, BCP was shown to 
potentiate the anticancer activity of paclitaxel (Legault and Pinchette, 2007). Taken together, 
combination therapies might offer the possibility of decreasing the doses of opioids, NSAIDs 
or paclitaxel and thereby reducing the risk of unwanted side effects. 
Compared to synthetic CB2 receptor agonists, BCP provides the clear advantage of an 
effective oral treatment as it is readily bioavailable and metabolized with a Tmax > 1h after a 
single oral administration (Gertsch et al., 2010). The most efficient dose-range in mice was 
between 1 and 5 mg/kg. To get first hints about the amounts of BCP a human has to ingest 
for sufficient receptor-binding, the human equivalent dose (HED) can be estimated. The US 
Food and Drug Administration suggested to calculate the HED based on normalization of the 
body surface areas (bsa):  
    (    ⁄ )              (    ⁄ )  
        
        
 , 
where the km value for mouse (km = 3) and a 60 kg human (km = 37) is based on body 
weight divided by bsa (Reagan-Shaw et al., 2008). Following this, a human daily dose of 
0.08-0.41 mg/kg BCP would correspond to the effective dose in mice. It was already 
estimated that the average daily intake of BCP with vegetable food and spices lies in the 
range of 10 to 200 mg (Gertsch et al., 2008), which would correspond to a dose of 0.16-
3.3 mg/kg for a 60 kg human. This dose would certainly be sufficient for significant CB2 
receptor activation, but further investigations have to be performed to get deeper insights 
about the impact of BCP on human health. 
5.5 Establishing a model of paclitaxel-induced 
neuropathic pain 
Paclitaxel, which naturally occurs in the bark of the Pacific yew (Taxus brevifolia), is 
widely used as an antineoplastic agent, specifically in ovarian and breast cancer therapy. It 
impedes the cell cycle in the late phase of mitosis by promoting microtubule assembly, which 
leads to the formation of abnormal microtubule arrays, interrupts normal cell function and 
finally leads to cell death (Scripture et al., 2006). Although these effects are desired for 
cancer therapy, it certainly also affects the healthy tissue. Paclitaxel accumulates in 
intermediate or low amounts in dorsal root ganglia, brain, spinal cord and sensory neurons 
(Cavaletti et al, 2000). In sensory neurons paclitaxel similarly promotes the formation of 
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microtubule aggregates, which impairs the axonal transport, results in sensory nerve 
demyelination and neuronal cell death (Masurovsky et al., 1981; Lipton et al., 1989; Apfel et 
al., 1991).  
Paclitaxel-evoked neuropathy is manifested as pain in the distal extremities, forming a 
glove and stocking pattern. It preferentially impairs myelinated A-β and to a lesser extent A-δ 
fibers, which carry sensory information about mechanical and cold stimulation to the spinal 
cord. Accordingly, patients suffer from an impaired perception of light touch, vibration and 
cold. In contrast, the sensitivity towards thermal heat stimuli is not altered (Dougherty et al., 
2004). 
Paclitaxel was also shown to induce neuropathic pain symptoms in rodents (Polomano et 
al., 2001; Smith et al., 2004). In mice, several strains were tested for development of 
mechanical allodynia, which was strain dependent with some strains appearing to be more 
sensitive (DBA/2), while other were less sensitive (C3H/He, C57BL/6). Two strains were 
further tested for thermal hyperalgesia and cold allodynia. While thermal thresholds remained 
unaffected, both strains developed cold allodynia (Smith et al., 2004). In rats also thermal 
hyperalgesia was found (Polomano et al., 2001). 
Few studies also focused on the role of CB2 receptors in paclitaxel-induced neuropathic 
pain. Similarly to traumatic nerve injury models, agonists like AM1241, AM1714 and MDA19 
reduced mechanical allodynia in a CB2 receptor-dependent manner (Rahn et al., 2007; Rahn 
et al., 2008; Xu et al., 2010). But the mechanisms by which CB2 receptor agonists modulate 
chemotherapeutic agent-induced neuropathic pain remains unknown - especially as it was 
found that astrocytes, but probably not microglia are involved in neuropathic pain after 
paclitaxel treatment (Zhang et al., 2012). 
To establish the paclitaxel-evoked neuropathic pain model in our laboratory, the protocol 
of Smith et al. (2004) was slightly adjusted and wild type C57BL/6J and CB2 knockout mice 
on the same background were tested. Although wild type mice slightly developed signs of 
mechanical allodynia, CB2 knockout mice exhibited a robust decrease in mechanical 
withdrawal latencies, while thermal withdrawal latencies remained unchanged as it was 
reported by Smith and colleagues. In a second round of experiments cold allodynia was also 
assessed. In contrast to the reports from the literature, none of the strains developed cold 
allodynia in these experiments. Differences between the present measurements and 
literature reports might arise from the different testing methods used. Smith et al. (2004) 
used von Frey hairs to test mechanical allodynia, while in the present study a dynamic 
aesthesiometer was used. Similar, Smith et al. (2004) applied the acetone method to 
measure cold allodynia and not the Cold plate test as used in our study.  
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Nevertheless, the present results suggest that CB2 receptor activation protects against 
paclitaxel-evoked neuropathic pain, which is in line with the results of traumatic nerve injury 
models (Rácz et al., 2008b; Rahn et al., 2008).  
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6 CONCLUSION AND OUTLOOK 
Summarized, the present study is the first demonstration that a common food ingredient is 
highly effective in an animal model of neuropathic pain at physiologically relevant doses. 
BCP is the first bioactive, natural CB2 receptor agonist, which is able to reduce neuropathic 
pain symptoms in mice, without exerting any CB1-associated psychomimetic side effects. 
Thus, it is likely that BCP belongs to a group of common plant products with a major potential 
impact on human health. The possibility of an oral intake of this dietary cannabinoid with 
vegetable food could be advantageous over other synthetic cannabinoid agonists in the daily 
clinical routine and improve current neuropathic pain therapies.  
The establishment of another animal model for neuropathic pain further stresses the 
crucial role of CB2 receptors in the development of neuropathic pain. Additional experiments 
might give deeper insights in CB2 receptor activation during paclitaxel-induced neuropathic 
pain by examining the immune responses in dorsal root ganglia and dorsal horns of the 
spinal cord. Using a more sensitive mouse strain than C57BL/6J mice, paclitaxel-induced 
neuropathic pain would certainly be a promising model to test the effects of BCP treatment, 
because BCP was also shown to potentiate the anticancer effects of paclitaxel (Legault and 
Pichette, 2007). A combined therapy of BCP and paclitaxel during cancer could therefore 
offer the opportunity of lowering the paclitaxel dose, which in turn reduces the risk of side 
effects (e.g. neuropathic pain symptoms) and, in parallel, may directly inhibit the 
development of neuropathic pain by CB2 receptor activation. 
LITERATURE 65 
 
7 LITERATURE 
APFEL SC, LIPTON RB, AREZZO JC and KESSLER JA (1991) Nerve growth factor 
prevents toxic neuropathy in mice. Ann Neurol 29(1): 87-90. 
BELTRAMO M, BERNARDINI N, BERTORELLI R, CAMPANELLA M, NICOLUSSI E, 
FREDDUZZI S and REGGIANI A (2006) CB2 receptor-mediated antihyperalgesia: 
possible direct involvement of neural mechanisms. Eu. J Neurosci 23(6): 1530-1538. 
BELTRAMO M (2009) Cannabinoid type 2 receptor as a target for chronic - pain. Mini Rev 
Med Chem 9(1): 11-25. 
BEN AMAR M (2006) Cannabinoids in medicine: A review of their therapeutic potential. J 
Ethnopharmacol 105(1-2): 1-25. 
BENITO C, ROMERO JP, TOLÓN RM, CLEMENTE D, DOCAGNE F, HILLARD CJ, GUAZA 
C and ROMERO J (2007) Cannabinoid CB1 and CB2 receptors and fatty acid amide 
hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J 
Neurosci 27(9): 2396-2402. 
BENTO AF, MARCON R, DUTRA RC, CLAUDINO RF, COLA M, LEITE DFP and CALIXTO 
JB (2011) β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through 
CB2 receptor activation and PPARγ pathway. Am J Pathol 178(3): 1153-1166. 
BERNARDES WA, LUCARINI R, TOZATTI MG, FLAUZINO LGB, SOUZA MGM, TURATTI 
ICC, ANDRADE E SILVA ML, MARTINS CHG, DA SILVA FILHO AA and CUNHA WR 
(2010) Antibacterial activity of the essential oil from Rosmarinus officinalis and its major 
components against oral pathogens. Z Naturforsch, C, J Biosci 65(9-10): 588-593. 
BREIVIK H, COLLETT B, VENTAFRIDDA V, COHEN R and GALLACHER D (2006) Survey 
of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 
10(4): 287-333. 
BUCKLEY NE, MCCOY KL, MEZEY E, BONNER T, ZIMMER A, FELDER CC, GLASS M 
and ZIMMER A (2000) Immunomodulation by cannabinoids is absent in mice deficient for 
the cannabinoid CB(2) receptor. Eur J Pharmacol 396(2-3): 141-149. 
CABRAL GA and MARCIANO-CABRAL F (2005) Cannabinoid receptors in microglia of the 
central nervous system: immune functional relevance. J Leukoc Biol 78(6): 1192-1197. 
CABRAL GA and GRIFFIN-THOMAS L (2009) Emerging role of the cannabinoid receptor 
CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol 
Med 11: 1-31. 
LITERATURE 66 
 
CALABRESE EJ (2008) Drug therapies for stroke and traumatic brain injury often display U-
shaped dose responses: occurrence, mechanisms, and clinical implications. Crit Rev 
Toxicol 38(6): 557-577. 
CAO H and ZHANG Y-Q (2008) Spinal glial activation contributes to pathological pain states. 
Neurosci Biobehav Rev 32(5): 972-983. 
CAVALETTI G, CAVALLETTI E, OGGIONI N, SOTTANI C, MINOIA C, D'INCALCI M, 
ZUCCHETTI M, MARMIROLI P and TREDICI G (2000) Distribution of paclitaxel within the 
nervous system of the rat after repeated intravenous administration. Neurotoxicology 
21(3): 389-393. 
CHOI Y, YOON YW, NA HS, KIM SH and CHUNG JM (1994) Behavioral signs of ongoing 
pain and cold allodynia in a rat model of neuropathic pain. Pain 59(3): 369-376. 
CLAPPER JR, MORENO-SANZ G, RUSSO R, GUIJARRO A, VACONDIO F, DURANTI A, 
TONTINI A, SANCHINI S, SCIOLINO NR, SPRADLEY JM, HOHMAN AG, CALIGNANO 
A, MOR M, TARZIA G and PIOMELLI D (2010) Anandamide suppresses pain initiation 
through a peripheral endocannabinoid mechanism. Nat Neurosci 13(10): 1265-70. 
COSTIGAN M, SCHOLZ J and WOOLF CJ (2009) Neuropathic pain: a maladaptive 
response of the nervous system to damage. Annu Rev Neurosci 32: 1-32. 
COULL JAM, BEGGS S, BOUDREAU D, BOIVIN D, TSUDA M, INOUE K, GRAVEL C, 
SALTER MW and DE KONINCK Y (2005) BDNF from microglia causes the shift in 
neuronal anion gradient underlying neuropathic pain. Nature 438(7070): 1017-1021. 
COX ML, HALLER VL and WELCH SP (2007) Synergy between Δ9-tetrahydrocannabinol 
and morphine in the arthritic rat. Eur. J. Pharmacol. 567(1-2): 125–130 
COYLE DE (1998) Partial peripheral nerve injury leads to activation of astroglia and microglia 
which parallels the development of allodynic behavior. Glia 23(1): 75-83. 
CUNHA TM, VERRI WA, SILVA JS, POOLE S, CUNHA FQ and FERREIRA SH (2005) A 
cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc 
Natl Acad Sci USA 102(5): 1755-1760. 
DE LEO JA, TAWFIK VL and LACROIX-FRALISH ML (2006) The tetrapartite synapse: path 
to CNS sensitization and chronic pain. Pain 122(1-2): 17-21. 
DEVOR M: Response to nerve injury in relation to neuropathic pain. In: Wall and Melzack´s 
textbook of pain, 5th edition (McMahon S,Koltzenburg M, Eds.), Elsevier Churchill 
Livingstone, London, 2006,  
DI SOTTO A, MAZZANTI G, CARBONE F, HRELIA P and MAFFEI F (2010) Inhibition by 
beta-caryophyllene of ethyl methanesulfonate-induced clastogenicity in cultured human 
lymphocytes. Mutat Res 699(1-2): 23-28. 
DOUGHERTY PM, CATA JP, CORDELLA JV, BURTON A and WENG H-R (2004) Taxol-
induced sensory disturbance is characterized by preferential impairment of myelinated 
fiber function in cancer patients. Pain 109(1-2): 132-142. 
DUNKIĆ V, BEZIĆ N and VUKO E (2011) Antiphytoviral activity of essential oil from endemic 
species Teucrium arduini. Nat Prod Commun 6(9): 1385-1388. 
DYSON A, PEACOCK M, CHEN A, COURADE J-P, YAQOOB M, GROARKE A, BRAIN C, 
LOONG Y and FOX A (2005) Antihyperalgesic properties of the cannabinoid CT-3 in 
chronic neuropathic and inflammatory pain states in the rat. Pain 116: 129–137. 
LITERATURE 67 
 
DZIADULEWICZ EK, BEVAN SJ, BRAIN CT, COOTE PR, CULSHAW AJ, DAVIS AJ, 
EDWARDS LJ, FISHER AJ, FOX AJ, GENTRY C, GROARKE A, HART TW, HUBER W, 
JAMES IF, KESINGLAND A, LA VECCHIA L, LOONG Y, LYOTHIER I, MCNAIR K, 
O'FARRELL C, PEACOCK M, PORTMANN R, SCHOPFER U, YAQOOB M, 
ZADROBILEK J (2007) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl) methanone: a 
potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties 
and restricted central nervous system penetration. J Med Chem 50: 3851-3856 3851. 
FACCI L, DAL TOSO R, ROMANELLO S, BURIANI A, SKAPER SD and LEON A (1995) 
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to 
anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92(8): 3376-3380. 
FINN DP, BECKETT SR, ROE CH, MADJD A, FONE KC, KENDALL DA, MARSDEN CA and 
CHAPMAN V (2004) Effects of coadministration of cannabinoids andmorphine on 
nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of 
persistent pain. Eur J Neurosci 19(3): 678–686. 
GAONI, Y and MECHOULAM, R (1971) The isolation and structure of delta-1-
tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 
93(1): 217-24. 
GARCIA-OVEJERO D, AREVALO-MARTIN A, PETROSINO S, DOCAGNE F, HAGEN C, 
BISOGNO T, WATANABE M, GUAZA C, DI MARZO V and MOLINA-HOLGADO E (2009) 
The endocannabinoid system is modulated in response to spinal cord injury in rats. 
Neurobiol Dis 33(1): 57-71. 
GERTSCH J (2008) Anti-inflammatory cannabinoids in diet: Towards a better understanding 
of CB(2) receptor action? Commun Integr Biol 1(1): 26-28. 
GERTSCH J, LEONTI M, RADUNER S, RÁCZ I, CHEN J-Z, XIE X-Q, ALTMANN K-H, 
KARSAK M and ZIMMER A (2008) Beta-caryophyllene is a dietary cannabinoid. Proc Natl 
Acad Sci USA 105(26): 9099-9104. 
GERTSCH J, PERTWEE RG and DI MARZO V (2010) Phytocannabinoids beyond the 
Cannabis plant - do they exist? Br J Pharmacol 160(3): 523-529. 
GHELARDINI C, GALEOTTI N, DI CESARE MANNELLI L, MAZZANTI G and BARTOLINI A 
(2001) Local anaesthetic activity of beta-caryophyllene. Farmaco 56(5-7): 387-389. 
GILRON I, WATSON CPN, CAHILL CM and MOULIN DE (2006) Neuropathic pain: a 
practical guide for the clinician. CMAJ 175(3): 265-275. 
GUINDON J, DE LÉAN A and BEAULIEU P (2006) Local interactions between anandamide, 
an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and 
inflammatory pain. Pain 121(1-2): 85–93. 
GUINDON J and HOHMANN AG (2008) Cannabinoid CB2 receptors: a therapeutic target for 
the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153(2): 319-334. 
HALD A (2009) Spinal astrogliosis in pain models: cause and effects. Cell Mol Neurobiol 
29(5): 609-619. 
HALD A, NEDERGAARD S, HANSEN RR, DING M and HEEGAARD A-M (2009) Differential 
activation of spinal cord glial cells in murine models of neuropathic and cancer pain. Eur J 
Pain 13(2): 138-145. 
LITERATURE 68 
 
HANUS L, BREUER A, TCHILIBON S, SHILOAH S, GOLDENBERG D, HOROWITZ M, 
PERTWEE RG, ROSS RA, MECHOULAM R and FRIDE E (1999) HU-308: a specific 
agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96(25): 
14228-14233. 
HERKENHAM M, LYNN AB, JOHNSON MR, MELVIN LS, DE COSTA BR and RICE KC 
(1991) Characterization and localization of cannabinoid receptors in rat brain: a 
quantitative in vitro autoradiographic study. J Neurosci 11(2): 563–583. 
HOHMANN AG, BRILEY EM and HERKENHAM M (1999). Pre- and postsynaptic distribution 
of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 822(1-2):17–25. 
HORVÁTH B, MUKHOPADHYAY P, KECHRID M, PATEL V, TANCHIAN G, WINK DA, 
GERTSCH J and PACHER P (2012) β-Caryophyllene ameliorates cisplatin-induced 
nephrotoxicity in a cannabinoid 2 receptor-dependent manner. Free Radic Biol Med 52(8): 
1325-1333. 
HOWLETT AC, BREIVOGEL CS, CHILDERS SR, DEADWYLER SA, HAMPSON RE and 
PORRINO LJ (2004) Cannabinoid physiology and pharmacology: 30 years of progress. 
Neuropharmacol 47 Suppl 1: 345-358. 
HSIEH GC, PAI M, CHANDRAN P, HOOKER BA, ZHU CZ, SALYERS AK, WENSINK EJ, 
ZHAN C, CARROLL WA, DART MJ, YAO BB, HONORE P and MEYER MD (2011) 
Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in 
chronic inflammatory and neuropathic pain models in rats. Brit J Pharmacol 162(2): 428-
440. 
HUANG M, SANCHEZ-MOREIAS AM, ABEL C, SOHRABI R, Lee S, GERSHENZON J and 
THOLL D (2012) The major volatile organic compound emitted from Arabidopsis thaliana 
flowers, the sesquiterpene (E)-β-caryophyllene, is a defense against a bacterial pathogen. 
New Phytol 193(4), 997-1008. 
HUDAIB M, SPERONI E, DI PIETRA AM and CAVRINI V (2002) GC/MS evaluation of thyme 
(Thymus vulgaris L.) oil composition and variations during the vegetative cycle. J Pharm 
Biomed Anal 29(4): 691-700. 
IBRAHIM MM, PORRECA F, LAI J, ALBRECHT PJ, RICE FL, KHODOROVA A, DAVAR G, 
MAKRIYANNIS A, VANDERAH TW, MATA HP and MALAN TP (2005) CB2 cannabinoid 
receptor activation produces antinociception by stimulating peripheral release of 
endogenous opioids. Proc Natl Acad Sci USA 102(8): 3093-3098. 
INOUE K and TSUDA M (2009) Microglia and neuropathic pain. Glia 57(14): 1469-1479. 
ISKEDJIAN M, BEREZA B, GORDON A, PIWKO C and EINARSON TR (2007) Meta-
analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. 
Curr Med Res Opin 23(1): 17-24. 
JAYAPRAKASHA GK, JAGAN MOHAN RAO L and SAKARIAH KK (2003) Volatile 
constituents from Cinnamomum zeylanicum fruit stalks and their antioxidant activities. J 
Agric Food Chem 51(15): 4344-4348. 
JHAVERI MD, RICHARDSON D, KENDALL DA, BARRETT DA and CHAPMAN V (2006) 
Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic 
Pain. J Neurosci 26(51):13318–13327. 
LITERATURE 69 
 
JI RR and WOOLF CJ (2001) Neuronal plasticity and signal transduction in nociceptive 
neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 
8(1): 1-10. 
JI R-R, KOHNO T, MOORE KA and WOOLF CJ (2003) Central sensitization and LTP: do 
pain and memory share similar mechanisms? Trends Neurosci 26(12): 696-705. 
JI R-R, KAWASAKI Y, ZHUANG Z-Y, WEN Y-R and DECOSTERD I (2006) Possible role of 
spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with 
focus on bFGF/JNK pathway. ngB 2(4): 259-269. 
JI R-R, GEREAU RW, MALCANGIO M and STRICHARTZ GR (2009) MAP kinase and pain. 
Brain Res Rev 60(1): 135-148. 
JULIUS D and BASBAUM AI (2001) Molecular mechanisms of nociception. Nature 
413(6852): 203-210. 
KARST M and WIPPERMANN S (2009) Cannabinoids against pain. Efficacy and strategies 
to reduce psychoactivity: a clinical perspective. Expert Opin Inv Drug 18(2): 125-133. 
KATONA I and FREUND TF (2012) Multiple functions of endocannabinoid signaling in the 
brain. Annu Rev Neurosci 35: 529-558. 
KELLER AF, BEGGS S, SALTER MW and DE KONICK Y (2007) Transformation of the 
output of spinal lamina I neurons after nerve injury and microglia stimulation underlying 
neuropathic pain. Mol. Pain 3:27 
KESWANI SC, POLLEY M, PARDO CA, GRIFFIN JW, MCARTHUR JC and HOKE A (2003) 
Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann 
Neurol 54(3): 287-296. 
KINSEY SG, LONG JZ, O´NEIL ST, ABDULLAH RA, POKLIS JL, BOGER DL, CRAVATT DF 
and LICHTMAN AH (2009) Blockade of Endocannabinoid-Degrading Enzymes Attenuates 
Neuropathic Pain. J Pharmacol Exp Ther 330(3): 902-10. 
KINSEY SG, MAHADEVAN A, ZHAO B, SUN H, NAIDU PS, RAZDAN RK, SELLEY DE, 
IMAD DAMAJ M and LICHTMAN AH (2011) The CB2 cannabinoid receptor-selective 
agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral 
effects. Neuropharmacol 60(2-3): 244-251. 
KLAUKE A-L; RÁCZ I, PRADIER B, MARKERT A, ZIMMER A, GERTSCH J and ZIMMER A 
The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts 
analgesic effects in models of inflammatory and neuropathic pain. in preparation 
KLEYER J, NICOLUSSI S, TAYLOR P, SIMONELLI D, FURGER E, ANDERLE P and 
GERTSCH J (2012) Cannabinoid receptor trafficking in peripheral cells is dynamically 
regulated by a binary biochemical switch. Biochem Pharmacol 83(10): 1393-1412. 
KREUTZBERG GW (1996) Microglia: a sensor for pathological events in the CNS. Trends 
Neurosci 19(8): 312-318. 
LEGAULT J and PICHETTE A (2007) Potentiating effect of beta-caryophyllene on anticancer 
activity of alpha-humulene, isocaryophyllene and paclitaxel. J Pharm Pharmacol 59(12): 
1643-1647. 
LEICHSENRING A, ANDRISKE M, BÄCKER I, STICHEL CC and LÜBBERT H (2009) 
Analgesic and anti-inflammatory effects of cannabinoid receptor agonists in a rat model of 
neuropathic pain. Naunyn-Schmied Arch Pharmacol 379(6): 627-636. 
LITERATURE 70 
 
LIPTON RB, APFEL SC, DUTCHER JP, ROSENBERG R, KAPLAN J, BERGER A, EINZIG 
AI, WIERNIK P and SCHAUMBURG HH (1989) Taxol produces a predominantly sensory 
neuropathy. Neurology 39(3): 368-373. 
LIVAK KJ and SCHMITTGEN TD (2001) Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4): 402-408. 
LUONGO L, PALAZZO E, TAMBARO S, GIORDANO C, GATTA L, SCAFURO MA, ROSSI 
FS, LAZZARI P, PANI L, DE NOVELLIS V, MALCANGIO M and MAIONE S (2010) 1-
(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-
carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional 
microglial changes in mice. Neurobiol Dis 37(1): 177-185. 
LÜTTGE U, KLUGE M and BAUER G: Die Naturstoffe: Pflanzen als vielseitige Synthetiker. 
In: Botanik, 5th edition, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2005 
LYNCH ME and CAMPBELL F (2011) Cannabinoids for treatment of chronic non-cancer 
pain; a systematic review of randomized trials. Br J Clin Pharmacol 72(5): 735-744. 
MAFFEI ME, GERTSCH J and APPENDINO G (2011) Plant volatiles: production, function 
and pharmacology. Nat Prod Rep 28(8): 1359-1380. 
MALFAIT AM, GALLILY R, SUMARIWALLA PF, MALIK AS, ANDREAKOS E, MECHOULAM 
R and FELDMANN M (2000) The nonpsychoactive cannabis constituent cannabidiol is an 
oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 
97(17): 9561-9566. 
MALMBERG AB and BASBAUM AI (1998) Partial sciatic nerve injury in the mouse as a 
model of neuropathic pain: behavioral and neuroanatomical correlates. Pain 76(1-2): 215-
222. 
MANSOUR A, KHACHATURIAN H, LEWIS ME, AKIL H and WATSON SJ (1988). Anatomy 
of CNS opioid receptors. Trends Neurosci 11(7): 308–314. 
MARESZ K, CARRIER EJ, PONOMAREV ED, HILLARD CJ and DITTEL BN (2005) 
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory 
stimuli. J Neurochem 95(2): 437-445. 
MARTIN BR, COMPTON DR, THOMAS BF, PRESCOTT WR, LITTLE PJ, RAZDAN RK, 
JOHNSON MR, MELVIN LS, MECHOULAM R and WARD SJ (1991) Behavioral, 
biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol 
Biochem Behav 40(3): 471-478. 
MASUROVSKY EB, PETERSON ER, CRAIN SM and HORWITZ SB (1981) Microtubule 
arrays in taxol-treated mouse dorsal root ganglion-spinal cord cultures. Brain Res. 217(2): 
392-398. 
MATSUDA LA., LOLAIT S J., BrROWNSTEIN MJ, YOUNG AC and BONNER TI (1990). 
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 
346(6284): 561-4. 
MC ALLISTER S and GLASS M (2002) CB1 and CB2 receptor-mediated signaling: a focus 
on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66(2-3): 161-71 
MILLIGAN ED and WATKINS LR (2009) Pathological and protective roles of glia in chronic 
pain. Nat Rev Neurosci 10(1): 23-36. 
LITERATURE 71 
 
MOCKUTE D, BERNOTIENE G and JUDZENTIENE A (2001) The essential oil of Origanum 
vulgare L. ssp. vulgare growing wild in vilnius district (Lithuania). Phytochemistry 57(1): 
65-69. 
MUNRO S., THOMAS KL and ABU-SHAAR M. (1993). Molecular characterization of a 
peripheral receptor for cannabinoids. Nature 365(6441): 61-5. 
NICOTRA L, LORAM LC, WATKINS LR and HUTCHINSON MR (2012) Toll-like receptors in 
chronic pain. Exp Neurol 234(2): 316-329. 
NIMMERJAHN A, KIRCHHOFF F and HELMCHEN F (2005) Resting microglial cells are 
highly dynamic surveillants of brain parenchyma in vivo. Science 308(5726): 1314-1318. 
ORAV A, STULOVA I, KAILAS T and MÜÜRISEPP M (2004) Effect of storage on the 
essential oil composition of Piper nigrum L. fruits of different ripening states. J Agric Food 
Chem 52(9): 2582-2586. 
PIOMELLI D (2003) The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 
4(11): 873-884. 
RÁCZ I, NADAL X, ALFERINK J, BANOS JE, REHNELT J, MARTIN M, PINTADO B, 
GUTIERREZ-ADAN A, SANGUINO E, BELLORA N, MANZANARES J, ZIMMER A and 
MALDONADO R (2008a) Interferon-γ Is a Critical Modulator of CB2 Cannabinoid 
Receptor Signaling during Neuropathic Pain. J Neurosci 28(46): 12136-12145. 
RÁCZ I, NADAL X, ALFERINK J, BANOS JE, REHNELT J, MARTIN M, PINTADO B, 
GUTIERREZ-ADAN A, SANGUINO E, MANZANARES J, ZIMMER A and MALDONADO 
R (2008b) Crucial Role of CB2 Cannabinoid Receptor in the Regulation of Central 
Immune Responses during Neuropathic Pain. J Neurosci 28(46): 12125-12135. 
RAHN EJ, ZVONOK AM, THAKUR GA, KHANOLKAR AD, MAKRIYANNIS A and 
HOHMANN AG (2008) Selective activation of cannabinoid CB2 receptors suppresses 
neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel 
in rats. J Pharmacol Exp Ther 327(2): 584-591. 
RAHN EJ, THAKUR GA, WOOD JAT, ZVONOK AM, MAKRIYANNIS A and HOHMANN AG 
(2011) Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist 
from the cannabilactone class: Antinociception without central nervous system side-
effects. Pharmacol Biochem Behav 98(4): 493-502. 
RECHE I, FUENTES JA and RUIZ-GAYO M (1996). Potentiation of D9-
tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of A- and n-
opioid receptors. Eur J Pharmacol 318(1): 11–16. 
ROMERO-SANDOVAL A and EISENACH JC (2007) Spinal cannabinoid receptor type 2 
activation reduces hypersensitivity and spinal cord glial activation after paw incision. 
Anesthesiology 106(4): 787-794. 
ROMERO-SANDOVAL E, HORVATH R, LANDRY RP and DELEO JA (2009) Cannabinoid 
receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces 
migration via MKP induction and ERK dephosphorylation. Mol Pain 5(1): 25. 
SALIO C, FISCHER J, FRANzoNI MF, MACKIE K, KANEKO T and CONRATH M (2001) 
CB1-cannabinoid and A-opioid co-local- ization on postsynaptic target in the rat dorsal 
horn. Neuroreport 12, 3689–3692. 
LITERATURE 72 
 
SAÑUDO-PEÑA MC, STRANGMAN NM, MACKIE K, WALKER JM and TSOU K (1999) CB1 
receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral 
nerve. Zhongguo Yao Li Xue Bao 20(12): 1115-1120. 
SCHÄFERS M, SVENSSON CI, SOMMER C and SORKIN LS (2003) Tumor necrosis factor-
alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK 
in primary sensory neurons. J Neurosci 23(7): 2517-2521. 
SCHOLZ J and WOOLF CJ (2007) The neuropathic pain triad: neurons, immune cells and 
glia. Nat Neurosci 10(11): 1361-1368. 
SHOEMAKER JL, RUCKLE MB, MAYEUX PR and PRATHER PL (2005) Agonist-Directed 
Trafficking of Response by Endocannabinoids Acting at CB2 Receptors. J Pharmacol Exp 
Ther 315(2): 828-38. 
SMITH BH and TORRANCE N (2012) Epidemiology of Neuropathic Pain and Its Impact on 
Quality of Life. Current pain and headache reports 16(3): 191-8 
SMITH SB, CRAGER SE and MOGIL JS (2004) Paclitaxel-induced neuropathic 
hypersensitivity in mice: responses in 10 inbred mouse strains. Life Sci 74(21): 2593-
2604. 
SOMMER C, PETRAUSCH S, LINDENLAUB T and TOYKA KV (1999) Neutralizing 
antibodies to interleukin 1-receptor reduce pain associated behav- ior in mice with 
experimental neuropathy. Neurosci Lett 270(1):25–8. 
SOUTH SM, KOHNO T, KASPAR BK, HEGARTY D, VISSEL B, DRAKE CT, OHATA M, 
JENAB S, SAILER AW, MALKMUS S, MASUYAMA T, HORNER P, BOGULAVSKY J, 
GAGE FH, YAKSH TL, WOOLF CJ, HEINEMANN SF and INTURRISI CE (2003) A 
conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal 
horn reduces NMDA currents and injury-induced pain. J Neurosci 23(12): 5031-5040. 
SULCOVA E, MECHOULAM R and FRIDE E (1998) Biphasic effects of anandamide. 
Pharmacol Biochem Behav 59(2): 347-352. 
STRAIKER A and MACKIE K (2006). Cannabinoids, electrophysiology, and retrograde 
messengers: challenges for the next 5 years. AAPS J 8(2): E272-6 
STREIT WJ and XUE QS (2009) Life and death of microglia. J Neuroimmune Pharmacol 
4(4): 371-379. 
TANGA FY, RAGHAVENDRA V and DELEO JA (2004) Quantitative real-time RT-PCR 
assessment of spinal microglial and astrocytic activation markers in a rat model of 
neuropathic pain. Neurochem Int 45(2-3): 397-407. 
TASSIULAS I, PARK-MIN K-H, HU Y, KELLERMAN L, MEVORACH D and IVASHKIV LB 
(2007) Apoptotic cells inhibit LPS-induced cytokine and chemokine production and IFN 
responses in macrophages. Hum Immunol 68(3): 156-164. 
THACKER MA, CLARK AK, MARCHAND F and MCMAHON SB (2007) Pathophysiology of 
peripheral neuropathic pain: Immune cells and molecules. Anesth Analg 105(3): 838-847. 
THAM SM, ANGUS JA, TUDOR EM and WRIGHT CE (2005). Synergistic and additive 
interactions of the cannabinoid agonist CP55,940 with μ opioid receptor and α2-
adrenoceptor agonists in acute pain models in mice. Br J Pharmacol 144(6): 875–884. 
LITERATURE 73 
 
ULUGÖL A, OZYIGIT F, YESILYURT O and DOGRUL A (2006). The additive anti-
nociceptive interaction between WIN 55,212-2, a cannabinoid agonist, and ketorolac. 
Anesth Analg 102(2): 443–447. 
VALLEJO R, TILLEY DM, VOGEL L and BENYAMIN R (2010) The role of glia and the 
immune system in the development and maintenance of neuropathic pain. Pain Pract 
10(3): 167-184. 
WAN G, YANG K, LIM QE, ZHOU L, HE BP, WONG HK and TOO H-P (2010) Identification 
and validation of reference genes for expression studies in a rat model of neuropathic 
pain. Biochem Biophys Res Commun 400(4): 575-580. 
WATKINS LR, MILLIGAN ED and MAIER SF (2001) Glial activation: a driving force for 
pathological pain. Trends Neurosci 24(8): 450-455. 
WEI Z, YANG H, LIU Z, TREMBLEY M, JOHNSTONE S, BÉHA S, YUE SY, SRIVASTAVA 
S, TOMASZEWSKI MJ, BROWN W, WALPOLE C, ST-ONGE S, LESSARD E, 
ARCHAMBAULT A-J, GROBLEWSKI T and PAGÉ D (2012) N-Methyl-3-(tetrahydro-2H-
pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of 
cannabinoid receptors agonists with low CNS penetration. Bioorg Med Chem Lett 22(12): 
3884-9. 
WELCH SP and STEVENS DL (1992) Anti-nociceptive activity of intrathecally administered 
cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 
262(1): 10–18. 
WILSON RI and NICOLL RA (2002) Endocannabinoid signaling in the brain. Science 
296(5568): 678-682. 
WOOLF CJ (1983) Evidence for a central component of post-injury pain hypersensitivity. 
Nature 306(5944): 686-688. 
WOOLF CJ and SALTER MW (2000) Neuronal plasticity: increasing the gain in pain. 
Science 288(5472): 1765-1769. 
YESILYURT O, DOGRUL A, GUL H, SEYREK M, KUSMEZ O, OZKAN Y and YILDIZ O 
(2003). Topical cannabinoid enhances topical morphine antinociception. Pain 105(1): 
303–308. 
ZHANG J, HOFFERT C, VU HK, GROBLEWSKI T, AHMAD S and O'DONNELL D (2003) 
Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not 
inflammatory chronic pain models. Eur J Neurosci 17(12): 2750-2754. 
ZHENG GQ, KENNEY PM and LAM LK (1992) Sesquiterpenes from clove (Eugenia 
caryophyllata) as potential anticarcinogenic agents. J Nat Prod 55(7): 999-1003. 
ZIAS J, STARK H, SELLGMAN J, LEVY R, WERKER E, BREUER A and MECHOULAM R 
(1993) Early medical use of cannabis. Nature 363(6426): 215. 
 
 
 
 
 
 
ACKNOWLEDGEMENT 74 
 
8 ACKNOWLEDGEMENT 
 
Danken möchte ich zunächst Herrn Prof. Dr. Andreas Zimmer für die Vergabe dieses 
spannenden Themas und die fortwährende, fachliche und persönliche Unterstützung 
während der gesamten Doktorarbeit. 
Herrn Prof. Dr. Horst Bleckmann danke ich für die Übernahme der Position als Gutachter 
meiner Doktorarbeit. 
Ganz besonders bedanken möchte ich mich bei Dr. Ildikó Rácz: Du hast mich nicht nur 
von Anfang an super in das Thema eingearbeitet, sondern du warst auch jederzeit bereit mir 
praktische Unterstützung bei einem Teil der Versuche und stetige Hilfe bei allen Dingen rund 
um die Doktorarbeit zu geben. Vielen Dank für die gute Zusammenarbeit!! 
Danken möchte ich auch Astrid Markert, Bruno Pradier und Anne Zimmer, die aktiv an 
einem Teil der Versuche beteiligt waren sowie Daniela Mauer für die Einarbeitung und Hilfe 
bei den Färbungen. Danke, ihr wart super!! 
Natürlich bedanke ich mich auch bei meinen Kollegen und Freunden aus dem Labor, 
ganz besonders Svenja, Alex, Eva, Ben, Britta, Pamela,…..aber auch allen anderen: Ohne 
euch wäre es natürlich nur halb so schön gewesen - und ich an manchen Tagen dafür 
doppelt so verzweifelt!  
Prof. Dr. Jürg Gertsch danke ich für die Bereitstellung des β-Caryophyllen und für die 
guten Denkanstöße bezüglich des Themas. 
Christina Müller, Eva Drews und Ildikó Rácz danke ich für die hilfreichen Korrekturen und 
die guten Ideen während dem Schreibprozess. 
Und zu Letzt ein unendlich langer Dank an meine Familie: schätze, ihr habt mich aus so 
einigen tiefen „Löchern“ während dieser Zeit wieder herausbekommen und mir den Rücken 
gestärkt, so dass die Arbeit jetzt endlich vollbracht ist. 
 
DAAANKE!!! 
 
